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ABSTRACT 
 
The increased prevalence of multi-drug resistant (MDR) Gram-negative infections in critically 
ill patients has resulted in the re-introduction of colistin as rescue therapy. Various guidelines 
for colistin administration have led to confusion in establishing the appropriate dose which 
has potential for adverse consequences including treatment failure or toxicity. Colistin, also 
known as Polymixin E, is a concentration-dependent bactericidal antibiotic considered to be 
highly nephrotoxic and neurotoxic. Colistin is used either intravenously to treat life 
threatening systemic infections or by nebulisation for the treatment of respiratory tract 
infections. Although colistin resistance has been documented in South Africa, there is no local 
evidence as to why and how colistin is used in hospitals and similarly compliance with current 
dosing guidelines is unknown. This study aimed to evaluate the utilization of colistin in order 
to identify stewardship opportunities regarding its’ appropriate use in the future.   
A retrospective electronic record review of adult patients treated with intravenous (IV) and 
aerosolised colistin therapy in four Gauteng private hospitals was conducted between 1 
September 2015 - 30 June 2016. The following data were collected on a standardized 
template; patient demographics including: age, gender, weight and hospital location; 
laboratory indicators including: renal function markers of creatinine and estimated 
Glomerular Filtration Rate (eGFR), as well as, culture specimens taken and their 
corresponding results. With regards to the colistin therapy: the indication for use, admitting 
diagnosis, the prescribed dose, frequency and route of administration, duration of treatment 
and if prescribed in combination with another Gram-negative antibiotic was considered. The 
following stewardship principles were monitored in addition to appropriate dose and 
duration; if a culture was taken prior to the initiation of treatment, if therapy was de-
escalated and if a loading dose was prescribed. Outcome measures included overall in-
hospital mortality, intensive care unit length of stay and overall hospital length of stay. 
Furthermore, compliance to two local colistin dosing guidelines was measured and a colistin 
stewardship bundle was developed, including nine process measures, to enhance the 
appropriate use of IV colistin. 
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A total of 237 patients were included in the study of which 212 received colistin IV and, 25 via 
nebulisation. The results of patients who received IV colistin therapy demonstrated an 81.2% 
overall compliance to the proposed colistin stewardship bundle developed from this study. 
Non-compliance was mainly due to incorrect maintenance doses prescribed (50%), ‘hang 
time’ (66%) and poor de-escalation practices (69%). Significantly shorter durations of 
treatment were found in patients who received higher loading doses (p=0.040) and in those 
that received maintenance doses of 4.5 Million Units (MU) twice daily vs 3 MU three times 
daily (p=0.0027). In addition, more of the patients that demised received the 3 MU three 
times daily maintenance doses, compared to those who survived (p=0.0037).   
 
Aerosolised colistin was only prescribed in one of the four hospitals studied. Of those patients 
who received aerosolised colistin, 13 were for cystic fibrosis and 12 for other nosocomial 
lower respiratory tract infections (LRTI’s). Compliance to appropriate dose for the cystic 
fibrosis patients was good at 92.3%, however, for other LRTI’s was poor at only 41.7%.    
This study demonstrated that there is noteworthy prevalence of MDR Gram-negative 
infections in South African hospitals which requires the use of colistin. In addition, the study 
identified many stewardship related opportunities to improve appropriate colistin utilization 
in particular relating to dose for both routes of administration. The implementation of a 
colistin stewardship bundle is necessary, as a matter of urgency, to preserve the efficacy of 
this last resort antibiotic.   
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CHAPTER ONE 
GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
1.1. A global view of antimicrobial resistance  
The discovery of antibiotics has been a critical resource to the advancement of modern 
medicine. Since the initial unearthing of antibiotics in the 1940’s, their essential role has 
contributed to the treatment of serious bacterial infections. Antibiotics have helped to 
prevent infections in surgeries and the immune compromised patient population; ultimately 
prolonging the life span of humans (CDDEP, 2015). Today, however, the efficacy of antibiotics 
is dwindling worldwide with the resultant emergence of life-threatening multidrug-resistant 
(MDR) bacteria. The persistent misuse (including under dosing, inappropriate duration and 
incorrect indications) of antibiotics globally has over time hastened the natural process of 
antibiotic resistance which Sir Alexander Fleming cautioned the public of in 1945. Antibiotic 
resistance is also known to be compounded as a consequence of antibiotic use which has 
been caused by two global factors: a) increased access to antibiotics due to increased earnings 
and availability and, b) a greater global demand for protein forcing the use of antibiotics as 
growth promoters in livestock (CDDEP, 2015). In line with natures mantra of ‘survival of the 
fittest;’ the larger the consumption of antibiotics and antibiotic pressure on a system, the 
higher the risk of MDR bacterial population selection (CDDEP, 2015).  
 
The ‘dawn of the post antibiotic era’ has been widely documented as a global threat to society 
which was echoed by the World health Organization (WHO, 2014).  It is estimated that by the 
year 2050, infections by antimicrobial resistant organisms will be the leading cause of death 
worldwide (one person dying every three seconds) (O’Neill, 2014). According to the Centre 
for disease Control and Prevention (2013) each year in the United States, two million patients 
are infected by MDR organisms, defined as resistance to more than three different classes of 
antimicrobials, of which 23000 patients succumb to these infections annually. The devastating 
consequences of this crisis includes increased hospital and antibiotic costs, prolonged hospital 
stays, poor patient outcomes and increased infection risks in hospitals and communities 
(CDDEP, 2015).  
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In addition, global health security has been compromised as a result of the advancements in 
aviation and population migration, which has provided an opportunistic platform for MDR 
organisms and other diseases to spread.  A recent review of global antimicrobial resistance 
highlighted that antibiotic resistance is no longer a forecast for the future but rather a 
phenomena that is currently occurring extensively worldwide and which requires imperative 
collective attention and action (WHO, 2014). Furthermore, a report entitled: “The state of the 
world’s antibiotics” exposed the alarming prevalence of MDR Gram-negative organisms 
especially amongst the Enterobacteriaceae (CDDEP, 2015). Low and middle income countries 
are particularly affected by antibiotic resistance due to the enhanced infection rates 
experienced, lack of infection surveillance programs in place, and the exorbitant costs 
associated with treating these in already weak and strained health systems (CDDEP, 2015).  
 
A global review of antibiotic consumption over a ten year period showed that utilization of 
antibiotics increased overall by 36%. The most notable increase in consumption was reflected 
in the carbapenem and polymixin classes of antibiotics (van Boeckel et al., 2014). This implies 
a greater global need for the use of broad-spectrum Gram-negative antibiotics in healthcare 
settings. Because these so-called ‘super-bugs’ have gained resistance mechanisms to almost 
all antibiotics currently available, the use of older, more toxic drugs such as colistin is 
necessary, as a last resort therapy to help treat severe infections particularly by MDR Gram-
negative pathogens (Goff et al., 2014).   
 
Experts predict that in the foreseeable future there will be no new antibiotics with novel 
mechanisms of action available for the treatment of Gram-positive and Gram-negative 
bacterial infections (Nation and Li, 2009; Yamamoto and Pop-Vicas, 2014). Unfortunately, 
there is limited support available within the pharmaceutical industry to promote research and 
development for antimicrobials because discovery and development of these agents is 
difficult and return on investment is poor (Rex et al., 2014). 
 
1.2. Gram-negative organisms and resistance 
Gram-negative bacilli are found within the natural environment including soil and water and 
are often characterized by resistance to multiple antibiotics (Vincenti et al., 2014). These 
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organisms pose a particular threat to hospital environments as they are the most widespread 
which cause nosocomial infections (Vincenti et al., 2014). The rates of MDR Gram-negative 
organisms are escalating at an alarming pace. A recent report by the Centre for Disease 
Dynamics Economics and Policy (2015) showed that resistance to all first line and last resort 
antibiotics is on the rise universally. The ESKAPE organisms including: Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanni, Pseudomonas 
aeruginosa, and Enterobacter species, have been recognized globally as the pathogens shown 
to be rapidly developing resistance for which therapeutic options are diminishing, especially 
in the critically ill hospital care setting (Rice, 2008; Boucher et al., 2009). 
 
In non-fermenting Gram-negative bacilli such as P. aeruginosa, MDR and extensive-drug 
resistance (XDR) may emerge following sequential chromosomal mutations, which may lead 
to the overproduction of intrinsic β-lactamases, such as AmpC and hyper-expression of efflux 
pumps, target modifications and cell permeability alterations (Ruppe et al., 2015). 
Pseudomonas aeruginosa also has the ability to acquire mobile genetic elements encoding for 
resistance, including carbapenemases (Ruppe et al., 2015). The spontaneous mutation rate 
for expression of resistance may occur as frequently as 1 in 106-7 wild type strains. This process 
may be accelerated by overuse of antibiotics with anti-pseudomonal activity particularly if 
therapy is prolonged (Ruppe et al., 2015). 
 
Historically resistance amongst Enterobacteriaceae began with the emergence of the β-
lactamase enzymes around thirty years ago which rendered certain β-lactam antibiotics 
including cephalosporins ineffective (Bradford et al., 2004). As a result of the global spread of 
extended spectrum β-lactamases (ESBL) amongst Enterobacteriaceae, carbapenems -which 
are a broader spectrum class of antibiotics that cover most resistant Gram-negative species, 
were increasingly used. In the simplistic explanation of this phenomenon, the selective 
pressure caused by antimicrobial overuse, in hospital and community settings, has driven 
these organisms to acquire such resistance mechanisms (Vincenti et al., 2014). 
 
Evidence of the first carbapenem resistant Enterobacteriaceae species was documented in 
1993 (Ah et al., 2014). Carbapenem resistance amongst the Enterobacteriaceae can occur 
through various mechanisms; however, the most common is through the production of 
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carbapenemases, a bacterial enzyme which hydrolyses carbapenems and all other β-lactam 
antibiotics including penicillins and cephalosporins. These carbapenemase-producing  
Enterobacteriaceae (CPE) often contain additional mechanisms of resistance to the 
aminoglycosides and the flouroquinolone class of antibiotics, rendering all standard antibiotic 
therapies ineffective (Brink et al., 2012). The CPE pathogens produce various epidemiological 
classes of carbapenemases including: Guiana extended-spectrum β-lactamases (GES), Verona 
integron-encoded metallo β-lactamases (VIM), oxacillinase-type carbapenemases (OXA-48 
and its derivatives) and New Delhi metallo-β -lactamase 1 (NDM-1), all of whom are a major 
concern and risk to modern medicine and healthcare systems today (Brink et al., 2012).  
 
The international spread of CPE is showcased through the discovery of the NDM-1 enzyme in 
particular.  This enzyme was first revealed in 2008 from a Swedish patient following travel to 
New Delhi, India (Johnson and Woodford, 2013). To date Enterobacteriaceae containing 
NDM-1 genes have been reported in over 70 countries across the world which indicates how 
rapidly these organisms can spread globally (Johnson and Woodford, 2013). It has also been 
detected in environmental samples including water reservoirs in India and Vietnam, indicating 
emergence in both hospital and community locations (Johnson and Woodford, 2013). Risk 
factors for CPE organisms include: previous antibiotic exposure, prolonged hospitalization, 
severe illness and surgery to name a few (Brink et al., 2012). Often, patients infected with 
CPE’s are treated with salvage agents such as tigecycline, colistin and or fosfomycin as last 
resort therapy for these life threatening infections (Brink et al., 2012).   
 
MDR Gram-negative organisms such as K. pneumoniae and P. aeruginosa are recognised as 
particularly life-threatening pathogens. Although patterns of resistance vary worldwide there 
is a definite increase in these organisms including the CPE’s which has resulted in the Centres 
for Disease Control naming this group of organisms one of the topmost critical antibiotic 
resistant challenges today (Karam et al., 2016).  
 
Mechanisms of bacterial resistance are not a novel phenomenon but rather something that 
has always intrinsically existed even prior to the discovery of antibiotics (Karam et al., 2016). 
Therefore, it is thought that the emergence and spread of resistant bacteria following 
antibiotic therapy is a result of the selection of naturally occurring resistant bacteria. This is 
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due to the destruction of sensitive bacteria following antibiotic therapy and the environment 
created for those resistant kinds to proliferate (Karam et al., 2016). The risk of carbapenem 
resistance occurring in Gram-negative pathogens has been shown to be 5.9 times higher in 
patients exposed to only one to three days of a carbapenem and 7.8 times higher in patients 
exposed to longer therapy (Armand-Lefevre et al., 2013). The Gram-negative pathogens are 
most likely to display resistance to multiple classes of antibiotics and there are three 
mechanisms in which resistance can occur, particularly to β-lactam antibiotics (Poole, 2001; 
Karam et al., 2016): 
a) The production of a β-lactamase enzyme which hydrolyses multiple antibiotics and 
can result from a single amino acid change (plasmid-mediated) of the conventionally 
produced enzyme. In addition, chromosomally-mediated enzymes known as AmpC β-
lactamases can also develop and have been detected in K. pneumoniae and P. 
aeruginosa.   
b) Closure of porin channels within the bacterial cell wall which results in the inability of 
antibiotics to penetrate the pathogen. This mechanism is most commonly seen in 
organisms resistant to the carbapenem class of antibiotics. 
c) Development of efflux pumps that can be intrinsic or acquired by the pathogen and 
which expel antibiotics out of the bacteria cell walls.  
 
The factors that result in the emergence of carbapenemase production have not been linked 
to the single exposure of a particular antibiotic but rather to the repetitive broad-spectrum 
exposure and prolonged duration of all antibiotic therapies (Karam et al., 2016). 
The escalating global prevalence of antibiotic resistant organisms requires antibiotic therapy 
to be optimized in an attempt to effectively manage these infections (Cassir et al., 2014). 
Optimising antibiotic therapy in the critically ill patient, requires a deep understanding of the 
PK and PD parameters of the antibiotic as well as the MIC of the organism (Goff and Nicolau, 
2013; Abdul-Aziz et al., 2015). When considering the PD of antibiotics, the antibiotic 
concentration achieved is directly related to the ability to exert bactericidal or bacteriostatic 
effects (Abdul-Aziz et al., 2015). The activity of an antibiotic is a result of the amount of free 
drug concentration available and this is influenced by drug, patient and/or severity of illness 
factors including: the hydrophilicity or lipophilicity of the drug affecting its’ volume of 
6 
 
distribution; degree of protein binding of the drug and the serum albumin levels of the 
patients; augmented renal clearance and degree of capillary leakage; amongst other factors 
which could influence the drugs absorption, distribution, metabolism and elimination (Abdul-
Aziz et al., 2015; Richards et al., 2015).   
 
Multidrug resistant organisms often have much higher MIC’s then their sensitive counterparts 
(Richards et al., 2015). Therefore, when attempting to treat MDR organisms, optimal drug 
concentrations required are considerably greater than those usually accepted to be sufficient 
(Richards et al., 2015). Recommendations of drug concentrations more than four times the 
MIC exist to ensure adequate therapeutic efficacy and prevent the selection of resistant 
pathogens in critically ill patients (Richards et al., 2015).  
In  January 2017, the first published case report of a carbapenem resistant K. pneumoniae 
wound isolate revealed plasmid-mediated resistance to 26 antibiotics - all antibiotics 
currently commercially available (Chen et al., 2017). This pathogen was identified from an 
elderly female patient with a history of multiple hospital admissions (in both India and United 
States of America) and frequent antibiotic exposure. The patient succumbed to the infection 
following bacteraemia and multiple organ failure due to the absence of antibiotic agents as 
effective therapy (Chen et al., 2017).  
 
This case generated much concern from the healthcare fraternity and public alike as it 
highlighted the current reality of antibiotic resistance and the imminent inability to treat 
severe bacterial infections (Chen et al., 2017). 
 
1.3.  Background to colistin 
Colistin, (trade name Colimycine® and also known as Polymixin E) is considered to be a highly 
nephrotoxic and neurotoxic concentration-dependent bactericidal antibiotic. It became 
accessible for use in the late 1950’s, however, its’ utilization diminished over time as newer 
‘less toxic’ antibiotics with more favorable safety profiles, such as the aminoglycosides, 
became available (Biswas et al., 2012 ; Pike and Saltiel, 2014).  Colistin can be used either 
intravenously (IV) to treat life threatening systemic infections or by nebulisation for the 
treatment of respiratory tract infections including ventilator associated pneumonia (Nation 
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et al., 2014; Gu et al., 2014). There are two kinds of colistin preparations available; the first is 
in the form of a sodium salt known as colistimethate sodium (CMS) which is an inactive pro-
drug that requires in vivo conversion to its’ active form, colistin; and the second is in the form 
of colistin Base Activity (CBA), based upon microbiological standardization (Nation et al., 
2014).  
 
Unfortunately, the current dosing guidelines for colistin administration are outdated and 
confusing as package insert information has not been revised with new information since its’ 
initial launch, therefore, healthcare practitioners are using decades old information to make 
clinical decisions if and when referring to the package insert (Nation et al., 2014). This 
information is still based on pharmacokinetic (PK) properties concluded from improper 
microbiological assay studies (Nation et al., 2014). An incongruity arises as a result of this 
methodology as continuous conversion from the inactive prodrug, CMS, to its active form, 
colistin, occurs during the incubation period of these assays. Therefore, it is difficult to 
establish what the exact blood concentration of active colistin was at the time of blood sample 
collection and thus, product information is based on inflated colistin concentration values (Li 
and Nation, 2006; Nation et al., 2014). A study by Ortwine et al. (2014) concludes that because 
of these discrepancies the dosing guideline of colistin in the package insert is inaccurate and 
thus, the appropriate use of colistin cannot completely be determined due to the inadequate 
PK and pharmacodynamic (PD) data available.  
 
Furthermore, colistin guidelines are complicated because the literature provides 
recommendations in international units (IU) and milligrams (mg) of CMS, as well as the mg of 
CBA. The recommendations also differ between European and American literature depending 
on which metric convention the country adopts (Biswas et al., 2012). As a result, there is a 
misunderstanding in establishing the appropriate therapeutic dose of colistin which often 
results in the incorrect dose being administered to the patient (Nation et al., 2014). These 
pharmacological concerns further compromise the management of patients with life-
threatening Gram-negative infections who are on colistin treatment (Kassamali et al., 2013). 
If colistin is not dosed appropriately it can take 2-3 days to reach steady state concentration 
and thus the administration of a loading dose is essential to improved patient outcomes. Sub-
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therapeutic doses of colistin prohibit the drug from achieving optimal tissue concentrations 
for bacterial killing and are therefore ineffective (Kassamali et al., 2015).  
  
In South Africa, colistin is available in the IU of CMS as a Section 21 medicine since it is not 
registered for use in the country (Visser-Kift et al., 2014). It can be procured according to the 
Medicines and Related Substances Control Act (MRSCA) through special application and 
approval granted by the Medicines Control Council (MCC). Often, this approval process can 
lead to a delay in therapy which ultimately can have detrimental effects for the patient (Tigen 
et al., 2013; Wertheim et al., 2013).  This onerous process makes colistin unique as it is the 
only antibiotic ‘restricted’ as a result of it not being registered for use in the country (Nation 
et al., 2014). Therefore, colistin in South Africa is only authorized in critical and crucial 
circumstances as stipulated by the MRSCA (Act 101 of 1965). 
 
As a result of the mounting prevalence of MDR and XDR Enterobacteriaceae (such as 
K.pneumoniae) and non-fermentative  Gram-negative pathogens particularly P. aeruginosa, 
and A. baumanii, globally and in South Africa, polymixins are often the only remaining class 
of antibiotic that can be used as a final treatment option in critically ill patients (Li et al., 2006).  
New data suggests that the adverse effects of nephrotoxicity previously reported with the 
initial use of colistin was indeed a consequence of a misunderstanding of the antibiotics’ PK 
and PD properties and inappropriate dosing due to confusion and variations in the dosing 
metrics adopted by different countries (Dalfino et al., 2012; Nation et al., 2014; Nation et al., 
2017). As such, limited recent data supports the neurotoxic nature of colistin and some 
studies have suggested similar or safer toxicity profiles of colistin compared to the 
aminoglycosides when considering nephrotoxicity (Li et al., 2006). In most instances, the 
reported side effects of colistin are not long lasting and have been described to dissipate 
following discontinuation of therapy (Li et al., 2006; Dalfino et al., 2012). The risk-benefit ratio 
of prescribing colistin requires consideration in the fight against severe MDR and XDR 
infections.  
 
In early 2017, Nation and colleagues described a novel algorithmic approach for IV colistin 
dosing following interpretation of results from a large multi-centre PK study including 215 
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patients. This study established for the first time colistin dosing recommendations which were 
based on accurate PK data.  
 
Utilization reviews on colistin are scarce since the antibiotics’ use diminished from the market 
following the introduction of the aminoglycoside antibiotics in the early 1960’s (Biswas et al., 
2012 ; Pike and Saltiel, 2014). A search conducted on global databases including Pubmed and 
Science-Direct resulted in five studies relating to colistin utilization reviews (Table 1.1). The 
subsequent gap in the availability of literature over numerous years has left many questions 
regarding the appropriate use of colistin unanswered. In recent years, literature on colistin 
has become more abundant as a direct consequence of the worldwide emergence of MDR 
Gram-negative bacteria, ultimately resurrecting the use of colistin (Landersdorfer and Nation, 
2015).  
 
Table 1.1. A summary of publications pertaining to previously conducted colistin utilization 
reviews worldwide 
 Country 
Number of 
hospitals included 
in the study 
Number of patients 
meeting the study 
inclusion criteria 
Reference 
 Greece One 24  (Markou et al., 2003) 
 Greece One 43  (Michalopoulos et al., 2005) 
 Canada Twelve 22  (Sabuda et al., 2008) 
 Greece One 258  (Falagas et al., 2009) 
 Brazil One 109  (Tanita et al., 2013) 
 
 
It is not surprising that the early utilization studies on colistin were derived mostly from 
healthcare settings in Greece, as Miyakis et al. (2011) demonstrated, the country had one of 
the highest rates of MDR organisms in Europe according to European surveillance data 
reports from 2009, thus necessitating the need for colistin as salvage therapy as a direct 
consequence of the increased antibiotic resistance rates experienced.     
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The studies (Table 1.1) collected data similar to the scope of this study including; patient 
demographics, indication for use, organism resistance patterns, colistin dose, duration of 
therapy, effects on renal function, and overall outcome. The aims of these studies varied 
slightly but each contributed to the body of knowledge as they described their experiences 
with colistin in hospitals following the global rise of antibiotic resistance.  
 
1.4. Intravenous colistin dosing in the critically ill patient population 
It has been shown that patient outcomes improve and mortality is reduced with the timeous 
and appropriate administration of antibiotic therapy (Kumar et al., 2006). The benefits of 
administering the correct drug, however, are often reversed by suboptimal drug 
concentrations in vivo as a direct consequence of inappropriate dosing (Dalfino et al., 2012). 
Therefore, the prescription of the right drug at the right dose (cornerstones of antibiotic 
stewardship) is imperative to safeguard favourable patient outcomes and aid the resolution 
of infectious diseases. Dosing strategies of antibiotics are often devised from studies 
undertaken in patients who are not critically ill and therefore achieving the appropriate 
antibiotic dose in these at risk patients is a challenge (Roberts et al., 2014). As a result, the 
mortality rates are high and outcomes often poor for the critically ill (Roberts et al., 2014) and 
thus, it is imperative that dosing is accurate for these patients in order for them to have the 
best possible chance of survival.  
Optimising antibiotic dosing in the critically ill is complex due to the altered physiological state 
of the host such as: increased volumes of distribution and prevalence of organ dysfunction 
both affecting the PD of the drug (Roberts et al., 2014). This is further compounded by higher 
organism resistance rates (Richards et al., 2015). These factors make the attainment of the 
Minimum Inhibitory Concentration (MIC) required for the appropriate bactericidal or 
bacteriostatic antibiotic effect extremely problematic in these patients as often MIC’s can be 
doubled or tripled as a result of MDR.   
The optimization of antibiotic dosing is based on the PK and PD properties of the drug. The 
aim of these principles is to ensure that the suitable concentration of antibiotic is at the tissue 
site target in order to destroy or inhibit the growth of the infecting bacteria. The PK of 
antibiotics can be classified as either: a) time dependant agents, where a specific time is 
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required above the MIC (Time > MIC) to execute efficacy or, b) concentration dependant 
agents, where the area under the inhibitory curve (AUIC) to the MIC or concentration peak > 
MIC is important for effect (Figure 1.1) (Richards et al., 2015). The significance of optimal 
dosing cannot be stressed enough, as sub-therapeutic doses can lead to treatment failure and 
antibiotic resistance, whilst over dosing can lead to toxicities and side effects (Landersdorfer 
and Nation, 2015). The range of dosing of a drug which allows the exertion of its therapeutic 
effect safely is known as the ‘drug therapeutic window’ and drug prescribing, dosing and 
frequency of administration should aim to fall within this window (Landersdorfer and Nation, 
2015). This is difficult for drugs that have narrow therapeutic windows, such as colistin, as the 
difference in serum concentrations between efficacies (antibiotic effect), safety and toxicity 
(nephrotoxicity) is slight (Landersdorfer and Nation, 2015).      
 
Figure 1.1. The pharmacokinetics of antibiotics adapted from Richards et al., 2015. (MIC = 
Minimum inhibitory concentration; Time > MIC = time above the MIC; AUIC = area under 
the inhibitory curve) 
 
As mentioned, colistin was brought to market in the early 1960’s and was not subjected to 
the stringent drug development safety and efficacy studies as would be required today by 
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organisations such as the Food and Drug Administration (FDA) and locally the MCC (Nation 
and Li, 2009). Furthermore, many dosing guidelines of colistin, including those of the package 
insert, have been based on decades old information from inaccurate kinetic studies and 
therefore much of the information to date required to understand the appropriate use of 
colistin has been invalid or unknown (Garonzik et al., 2011; Nation et al., 2014; Landersdorfer 
and Nation, 2015).  
 Since colistin is administered as a prodrug (CMS), it was difficult to establish the exact 
concentration of colistin in blood samples drawn during PK studies (Nation et al., 2014). To 
overcome this, in recent years, researchers placed extracted samples on ice and immediately 
centrifuged these at low temperatures. The resultant plasma was then stored at between -
70°C and -80°C to prevent in vitro conversion of CMS to colistin (Plachouras et al., 2009; 
Garonzik et al., 2011). Additional studies also showed that an estimated 60% - 80% of inactive 
CMS is excreted unchanged in the urine suggesting that the conversion rate of CMS to active 
colistin in vivo is very slow, with maximum concentrations achieved approximately seven 
hours after each dose. This highlights the inefficiencies of CMS as a prodrug (Michalopoulos 
and Falagas, 2011; Ortwine et al., 2014; Landersdorfer and Nation, 2015). 
Plachouras and colleagues (2009), published the first report of population pharmacokinetics 
following IV colistin administration in critically ill patients. Although the study only included a 
sample of 18 patients, a better understanding of colistin dosing was brought to light. Many 
important findings were revealed including; 
 The half-life of the inactive prodrug, CMS, was 2.3 hours. 
 The half-life of the active drug colistin was 14.4 hours. This was later found to vary 
between patients (Nation et al., 2017). 
 Based on previously recommended dosing guidance of 3 MU eight hourly, it would 
take three days for colistin to reach a plasma concentration of 2 mg/L (the 
recommended MIC break point). 
 The administration of a colistin loading dose (9 MU or 12 MU) allowed for the 
attainment of the recommended MIC breakpoint much faster (Figure 1.2). 
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The implication of these findings were ground-breaking in obtaining a better understanding 
of how colistin should be dosed and provided the necessary evidence for a colistin loading 
dose, as it was demonstrated that the administration of a colistin loading dose ensures the 
quickest attainment of the MIC breakpoint (therapeutic colistin concentrations) resulting in 
optimised patient care (Plachouras et al., 2009; Karaiskos et al., 2015). The impact of these 
findings was verified by Mohamed et al. (2012), who showed that the administration of a 9 
MU colistin loading dose was associated with a rapid increase in the bactericidal effect of the 
drug within the first six and a half hours of treatment.  
 
Figure 1.2. The Pharmacokinetic predicted model of colistin concentrations in a typical 
patient following the administration of various colistin dosing strategies as described by 
Plachouras et al., 2009.  
 
Garonzik and colleagues (2011), expanded on the study by Plachouras et al. (2009) and 
published PK data following colistin IV administration in 105 patients including 12 patients on 
haemodialysis and four on continuous renal replacement therapy. The study made detailed 
colistin loading and maintenance dose suggestions for various categories of renal function 
and also based on body weight (Garonzik et al., 2011; Roberts and Lipman, 2012). Both studies 
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by Plachouras et al. (2009) and Garonzik et al. (2011), recommended higher daily doses of 
colistin that had previously ever been recorded or used.  
The outcomes of these studies were confirmed by Dalfino et al. (2012), who showed that 
loading patients with 9 MU of colistin and administering a 4.5 MU dose every 12 hours 
totalling an average daily dose of 9 MU (rather than 3 MU every 8 hours) resulted in a clinical 
cure rate of 82% in the 25 study patients. The study thus advocated for the administration of 
a colistin loading dose followed by high individual doses administered at longer intervals. 
Furthermore, acute kidney injury was observed in 18% of colistin courses administered which 
was found not to be severe and the effects of which were reversed following course 
completion (Dalfino et al., 2012). Another study also found that patients who survived 
received higher colistin doses (9 MU per day in divided doses) with limited toxic side effects 
and concluded that the average daily dose of colistin was an independent factor for mortality 
(Falagas et al., 2009). In addition, studies by both Vicari et al. (2013) and Gibson et al. (2016) 
demonstrated better seven day clinical cure rates for patients who received high dose colistin. 
The aforementioned evidence reiterates the need to optimise colistin dosing to improve 
patient outcomes. 
In 2015, the European Medicines Agency (EMA) and the United States FDA also updated their 
colistin dosing recommendations, however; the recommendations made between the two 
agencies were conflicting (Nation et al., 2016). The FDA recommendations did not include 
that of a loading dose for colistin and often, in a large proportion of patients with varying 
categories of renal dysfunction, the necessary plasma concentrations were unattainable 
based on the dosing suggestions made by either organisation (Nation et al., 2016). Thus, 
global consensus on the appropriate dosing of colistin following the release of these updated 
recommendations could still not be reached and further added to the confusion in optimal 
colistin dosing; since all the evidence published until then were based on relatively small 
patient samples.   
The largest population IV colistin PK study conducted including 215 critically ill patients from 
three different countries with varying degrees of renal function was published in March 2017 
by Nation and colleagues. This study clarified the appropriate recommended daily dosing of 
colistin according to various categories of renal function for the first time (Nation et al., 2017).  
15 
 
The findings from this study demonstrated the influence of renal function on the elimination 
of colistin and the drastic inter patient variability observed even at similar renal function 
categories. This effect is most likely due to the patient dependant conversion of the inactive 
pro drug to its active form, colistin, in vivo (Nation et al., 2017). The inter patient variability of 
in vivo colistin conversion further contributes to the complexity of the appropriate dosing of 
colistin, however, the recommendations from this study provide a verified dosing guideline 
and best available data to date. In addition, the findings push the colistin dosing boundaries 
and indicate that patients should possibly receive higher doses than what is currently being 
utilised.  
 
1.5. Colistin dosing guidelines 
At the time this study was conducted, the international dosing guidelines from Nation and 
colleagues (2017) were not yet published. Therefore, the best available colistin dosing 
guidelines available for South Africa were used to evaluate and determine the accuracy and 
appropriateness of colistin doses prescribed for the study patients. These guidelines were 
based on the best available international and national evidence at the time of their 
compilation. As discussed previously, consensus on appropriate colistin dosing globally is 
lacking. The advantages and disadvantages of these guidelines are summarised in Table 1.2.  
 
Table 1.2: Advantages and disadvantages of available South African colistin dosing 
guidelines.  
South African Society of Clinical Pharmacy Colistin dosing guideline  
(Labuschagne et al., 2016) 
Advantages Disadvantages 
 Most recent South African colistin dosing 
guideline. 
 Comprehensive and specific dosing 
guideline for intravenous and inhaled 
colistin therapy in adults and peadiatrics. 
 Authored by a large panel of experts in 
pharmacokinetics and clinical pharmacy. 
 Dosing recommendations are made 
according to creatinine clearance 
which requires additional metrics to 
calculate including patient weight. 
 Recommendations not based 
according to randomised controlled 
trials. 
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South African Society of Clinical Pharmacy Colistin dosing guideline  
(Labuschagne et al., 2016) 
Advantages Disadvantages 
 Dosing recommendations are provided for 
various categories of renal function 
including renal replacement therapy. 
 Additional information is provided 
including reconstitution of colistin and 
administration guidance. 
 Definitive loading dose recommendations 
are made. 
 Dosing recommendations not tiered 
according to strength of available 
evidence. 
 Different frequencies of 
administration are provided for 
various categories of renal function 
which may cause confusion in clinical 
practice. 
 
Colistin Dosing Guideline (Visser-Kift et al., 2015) 
Advantages Disadvantages 
 Dosing recommendations are made 
according to GFR categories which is easier 
to retrieve from laboratory reports. 
 Dosing recommedations are provided as 
part of a systematic review of available 
literature at the time.  
 Dosing recommendations are provided for 
various categories of renal function 
including renal replacement therapy. 
 Additional information including: dose 
adjustment in renal failure, combination 
therapy, loading doses and a 
comprehensive discussion is provided. 
 Only 12 hourly frequency of dose 
administration recommendations are 
made in an attempt to standardise 
administration of colistin. 
 Recommendations are not based 
according to randomised controlled 
trials. 
 Dosing recommendations are not 
tiered according to strength of 
available evidence. 
 Loading dose recommedations are 
somewhat vague recommending 9-12 
MU. 
 Does not contain dosing 
recommendations for inhaled colistin 
therapy. 
  
1.6.  Colistin effects on renal function 
Colistimethate Sodium (prodrug) is excreted primarily through the kidneys via glomerular 
filtration and a small portion is thought to be removed via tubular secretion. In contrast, the 
bulk of colistin following glomerular filtration is absorbed via tubular reabsorption and 
therefore the exact mechanisms of colistin clearance remains ambiguous (Landersdorfer and 
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Nation, 2015). Figure 1.3 depicts the pharmacokinetics of the renal excretion mechanisms of 
CMS and colistin. The process of reabsorption of colistin through renal tubular cells is 
considered to be the most likely cause of resultant nephrotoxicity (Roberts and Lipman, 2012; 
Landersdorfer and Nation, 2015). 
As a consequence of this mechanism of clearance, those patients with decreased renal activity 
have a larger proportion of CMS converted to Colistin; as the elimination of CMS would be 
delayed as a result of the decrease in renal function, allowing more time and opportunity for 
CMS to be hydrolysed. For this reason, dose adjustments in patients with renal insufficiencies 
are necessary in order to avoid toxic plasma concentrations of colistin in vivo (Ortwine et al., 
2014).   
 
Figure 1.3. A schematic diagram of the mechanism of renal excretion of Colistimethate 
Sodium (CMS) and colistin. During normal kidney function, the thickness of the arrows 
represent the degree of clearance for each component (Adapated from Landersdorfer and 
Nation, 2015). 
Colistin related nephrotoxicity has been linked to drug concentrations (dose-dependent 
phenomenon) and duration of therapy (longer treatment periods) (Nation and Li, 2009; Pogue 
et al., 2011; Dalfino et al., 2012). Toxicity rates between 30-45% have been reported recently 
(Akajagbor et al., 2013). A study conducted in a young cohort of 66 patients with few 
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comorbidity covariates that could attribute to renal dysfunction found that 45% obtained a 
degree of renal dysfunction following exposure to colistin (Hartzell et al., 2009). The study 
also found that the likelihood of toxicity occurring was 3.7 times greater if therapy continued 
for more than two weeks (Hartzell et al., 2009). DeRyke and colleagues (2010) demonstrated 
that 33% of patients studied developed nephrotoxicity during the first five days of colistin 
therapy. In this study, risk factors for the development of toxicity included advanced age, 
elevated illness severity scores, previous hospital admission, treatment in an intensive care 
environment and, renal dysfunction prior to the commencement of colistin therapy. Results 
from a study conducted by Pogue et al. (2011) revealed that nephrotoxicity occurred in 43% 
of patients following treatment with a higher dose colistin, however, kidney injury was short 
lived and mortality rates were not different when comparing those patients who developed 
nephrotoxicity and those who did not.  
A systematic review of the literature relating to colistin induced nephrotoxicity conducted by 
Pike and Saltiel (2014) concluded that although the administration of colistin is associated 
with exceptionally high rates of nephrotoxicity, the toxicity is often reversible and does not 
warrant the discontinuation of therapy. This suggests that in patients where colistin may be 
the only viable treatment option, the risk benefit ratio should be considered and perhaps the 
associated toxicity can be managed once the infection has been resolved.       
 
1.7.  Prescription of colistin in combination with other Gram-negative spectrum       
antibiotics 
When attempting to treat MDR organisms, prescribers are often faced with the following 
options:  
a) Increase the doses of otherwise standard antibiotic regimens or,   
b) Use a combination of antibiotic therapies to exert a potentially novel effect on the 
bacteria (Roberts and Lipman, 2012). 
The rationale for the prescription of colistin in combination with other Gram-negative 
antibiotic agents is to create synergy; a phenomenon whereby the combination of the two 
antibiotics creates an effect or exerts an efficacy that is greater than their individual 
contributions.  
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Patients with adequate renal function clear CMS, faster and therefore lower concentrations 
of the prodrug is available in the plasma for conversion to active colistin in vivo – a process 
further compounded by the slow conversion rate previously described. As such combination 
therapy is strongly advocated in patients with good renal function (CrCl >80 mL/min) for a 
synergistic antibiotic effect and to attain the required plasma MIC for bacterial killing 
(Landersdorfer and Nation, 2015; Nation et al., 2017). Furthermore, the recommended daily 
dose of patients with adequate renal function according to Nation et al. (2017) is 10 MU. Since 
the risk of colistin-associated nephrotoxicity is increased at this dose, it is recommended that 
colistin is administered at a maximum daily dose of 9 MU and combined with an additional 
Gram-negative spectrum antibiotic for synergy to achieve therapeutic efficacy (Nation et al., 
2017). In addition, since reports of colistin resistance have surfaced globally, administering 
colistin in combination is a method that could curtail the development of resistance to 
colistin, compared to the continuous use of colistin in monotherapy (Nation and Li, 2009; 
Visser-Kift et al., 2014; Richards et al., 2015; Coetzee et al., 2016). 
Colistin combination therapy has also been studied for the treatment of CPE infections in the 
critically ill since routine antibiotic regimens were rendered ineffective as a result of the 
emergence of these pathogens. Numerous observational studies have shown some success 
in using this strategy for the treatment of carbapenem resistant Gram-negative infections and 
as such, this has become the standard of care (Paul et al., 2014). However, there is very limited 
evidence to show that combination therapy improves clinical outcomes (Paul et al., 2014). 
Dalfino and colleagues (2012) initiated colistin monotherapy in 50% of study patients and 
found no difference in clinical cure compared to those patients who received combination 
therapy. Durante-Mangoni et al. (2013) studied the effects of colistin-rifampicin combination 
compared to colistin alone for XDR A. baumannii infections and found no change in 30-day 
mortality, infection related death or length of hospital stay in the two patient groups. 
Parchem et al. (2016) showed significant results with the administration of colistin 
combination therapy for microbiological cure but this was not found for clinical cure when 
compared to patients on monotherapy. In contrast, however, Daikos and colleagues (2014) 
demonstrated that significantly higher mortality rates were found in patients with 
carbapenemase producing blood stream infections treated with monotherapy compared to 
those treated with combination therapy.   
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An in vitro analysis of the activity of colistin alone versus in combination with carbapenems 
indicated that doripenem most consistently achieved synergistic effects and in general the 
co-administration of colistin and a carbapenem showed enhanced bactericidal efficacy and 
no evidence of emergence of resistance (Zusman et al., 2013). A systematic review of the 
available evidence including 20 articles for the treatment of CPE infections revealed that 
numerous combinations of adjunctive therapy to colistin have been tested with varying 
degrees of success, albeit in small patient populations and, significant variations regarding 
site and severity of infection. The review concluded that combinations of tigecycline-colistin 
and colistin-carbapenem may result in lower mortalities for infections caused by Klebsiella 
spp. (Falagas et al., 2014). One study also suggested triple therapy of colistin-tigecycline-
carbapenem as a strategy to combat these infections (Falagas et al., 2014).  
The disadvantages of combination therapy includes increased treatment costs, and risks of 
drug related toxicity with the patients’ broad exposure to antibiotics (Bergen et al., 2015). In 
addition, it is unclear if higher dosing of colistin has better outcomes than the administration 
of combination therapy (Delfino et al., 2012). A study including 12 countries sought to 
establish the effect of combination therapy versus monotherapy and mortality in patients 
with MDR blood stream infections for the first time. The most common combinations 
described in the study included: colistin-tigecycline (31%), aminoglycoside-tigecycline (35%) 
and colistin-carbapenem (44%) (Gutierrez-Gutierrez et al., 2017). Combinations including 
tigecycline, the aminoglycosides and colistin were associated with better outcomes compared 
to colistin monotherapy. However, due to the small sample of patients, the advantageous 
effects of the addition of a carbapenem to colistin could not be established. The study 
concluded that combination therapy was associated with improved survival rates only in 
patients that had high illness severity scores and that monotherapy should be used in patients 
with low scores (Gutierrez-Gutierrez et al., 2017).  
There are many unanswered questions regarding the outcome of combination antibiotic 
therapy and verification of the effectiveness of this strategy versus monotherapy is currently 
underway internationally by other study groups in a randomised control trial (Gutierrez-
Gutierrez et al., 2017). To date, the evidence is based on small, retrospective cohort type 
analysis (Falagas et al., 2014). Until additional evidence is available, the prescription of colistin 
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combination therapy is still recommended as best practice (Richards et al., 2015; Coetzee et 
al., 2016).    
 
1.8.  Inhaled colistin therapy 
The delivery of active therapeutic compounds directly to the respiratory tract dates back to 
the times of ancient Greek mythology where tales are told of the oracle of Delphi inhaling 
fumes from the temple of Apollo (Wenzler et al., 2016). In 1932, Whitlaw and Patterson 
termed the word ‘aerosol’ directly meaning air (aer) solution (sol) (Wenzler et al., 2016). Over 
the years many drug delivery advancements to the respiratory tract have been made 
culminating in the use of aerosolised antibiotics for the treatment of bacterial infections of 
the airways; since these infections are thought to be the most common cause of human illness 
in both in- and out- patient settings (Wenzler et al., 2016).  
It is shared knowledge that the effectiveness of antibiotic therapy relies on the achievement 
of sufficient concentrations of drug at the infection target site. Unfortunately, infections of 
the lower respiratory tract, such as pneumonia, are often difficult to treat as suboptimal 
concentrations of the drug penetrate the lung parenchyma to reach the deep alveolar level 
of the airways following systemic administration (Wenzler et al., 2016). To circumvent this, 
the delivery of the drug directly into the lungs, via inhalation, ensures optimal drug 
concentrations are achieved for microbial killing at the infection site whilst limiting the 
unintended consequences of commonly accompanying adverse effects, toxicities and the 
possible development of MDR intestinal flora that is associated with systemic delivery and 
exposure (Kofteridis et al., 2010; Tumbarello et al., 2013; Wenzler et al., 2016; Wunderink, 
2016). 
It is important to consider the practicality of inhaled drug delivery. Some of this includes 
consideration of the actual device used for aerosolisation (nebulizers versus dry powder 
inhalers), the size of drug droplets formed and the distribution of these in the lungs - small 
particles gravitate towards the lower airways including the bronchioles and alveoli compared 
to large particles which stay in the upper airways (Michalopoulos and Papadakis, 2010). The 
PK and PD of inhaled antibiotics are challenging, thus determining the link of drug delivery 
and clinical outcome is complex (Wenzler et al., 2016). Due to the lack of robust clinical data 
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and low numbers of large randomised controlled trials to establish accurate efficacy, the 
widespread use of aerosolised antibiotic administration is limited.  
Colistimethate Sodium can be administered through nebulisation, the effects of which are 
complicated by it requiring conversion to its active form. Frequently occurring reported side 
effects, albeit reversible, of inhaled colistin include: cough, tightness of the chest, 
bronchoconstriction as a result of histamine release and, apnea due to neuromuscular 
blockade (Cunningham et al., 2001; Westerman et al., 2004; Michalopoulos and Papadakis, 
2010;). As such, the concomitant prescription of a β-2 agonist (bronchodilator) is 
recommended (Beringer, 2001).  
In South Africa, the IV colistin formulation is reconstituted and nebulised. However, this IV 
formulation foams profusely when used for nebulisation which enhances the complexity of 
optimising drug delivery (Beringer, 2001). This is in contrast to the aerosolised colistin 
preparations available in Europe, including dry powder inhalers and specially prepared colistin 
solutions for nebulisation.  
Of concern, is the poor patient outcomes related to nosocomial pneumonia, including 
ventilator-associated pneumonia (VAP), affecting 10-20% of critically ill patients on 
mechanical ventilators in hospitals (Tumbarello et al., 2013). In these circumstances, mortality 
is affected by co-morbid diseases and the virulence of the infecting organism which is further 
compounded by MDR. Recently it has been recommended that aerosolised antibiotics should 
be used routinely, given the high failure rates of IV therapy and the current context of MDR 
infections for patients with VAP (Wunderink, 2016). Although, experience is limited with the 
use of aerosolised colistin for the treatment of  critically ill patients with MDR Gram-negative 
lower respiratory tract infections (LRTI’s), a plethora of evidence exists for its use in patients 
with cystic fibrosis (CF) and the prevention and treatment of P. aeruginosa (Falagas et al., 
2006; Wenzler et al., 2016). 
 
1.9.  Review of cystic fibrosis 
In the western world CF is one of the most common congenital hereditary diseases 
characterised by recurrent LRTI’s (Li et al., 2001). It affects 1 in 2500 births per year and over 
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70 000 people in the world today are currently living with the condition (Doring et al., 2000; 
Ciofu et al., 2015). Infection of the airways in CF is recognized as the biggest contributor to 
morbidity and mortality causing over 90% of patients to succumb to the condition (Doring et 
al., 2000; Langan et al., 2015). The disease is a ramification of a single genetic mutation of 
chromosome seven which causes reduced production of chloride and water secretions in the 
airways and results in the development of thick, viscous secretions and diminished 
mucociliary clearance (Doring et al., 2000; Hoiby, 2011). Therefore, elimination of inhaled 
bacteria from the lungs is inhibited allowing pathogenic organisms to harbour and cause 
colonisation and infection within the respiratory tract. Consequently, in the fight against 
infection, the patient’s non-inflammatory defence mechanisms breakdown, triggering a 
premature response of the inflammatory defence mechanisms including: polymorphonuclear 
leukocytes, cytokines and antibodies in the airways. The intense inflammatory response 
ultimately results in severe lung tissue damage (Hoiby, 2011).   
Patients with CF are prone to repeated and persistent respiratory tract infections from early 
childhood which can lead to respiratory failure, lung transplantation or death (Hoiby, 2011; 
Koerner-Rettberg and Ballmann, 2014). The timeous and aggressive treatment with antibiotic 
therapy can extend the CF patient’s life expectancy to 35-50 years, however, if left 
unattended to this can be drastically reduced (Hoiby, 2011). The primary aim of antibiotic 
therapy in CF is to steady lung function, prevent further lung tissue damage and if possible, 
reinstate previously diminished lung function (Hodson et al., 2002; Dalhoff, 2014). Although 
it is currently unclear if CF patients benefit more from aerosolised therapy compared to IV or 
oral, this method of drug delivery has certainly minimized the treatment burden and 
increased treatment compliance for these patients - as medication can be administered at 
home – and, it ensures sufficient therapeutic drug concentrations within the lungs whilst 
limiting associated systemic adverse effects (Dalhoff, 2014; Koerner-Rettberg and Ballmann, 
2014).  
In CF patients of all ages, P. aeruginosa is the most commonly identified opportunistic bacteria 
in sputum and bronchial washing samples (Doring et al., 2000; Li et al., 2001; Hodson et al., 
2002; Hoiby, 2011). This organism is known to be responsible for the on-going lung damage 
and the consequent respiratory failure that transpires from the disease as an approximate 2% 
of lung function is thought to diminish each year once chronic infection has been established 
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(Li et al., 2001; Hodson et al., 2002). It is estimated that 81.3% of CF patients between the 
ages of 26-30 are infected with P. aeruginosa and spread is thought to occur via direct 
transmission from one patient to another or via contaminants in the environment (Doring et 
al., 2000; Ciofu et al., 2015). 
There are two types of P. aeruginosa identified through the stages of CF infection illustrating 
the adaptive mechanism of the organism (Hoiby, 2011; Ciofu et al., 2015). Non-mucoid P. 
aeruginosa is typically recognized in initial infection episodes and is more responsive to 
antibiotic therapy compared to mucoid P. aeruginosa (Langan et al., 2015). The mucoid type 
often indicates chronic infection and contains a biofilm layer making the infiltration of 
antibiotics extremely difficult (Doring et al., 2000; Ciofu et al., 2015; Stefani et al., 2017). 
Biofilms are ever-present in nature, the components of which are often produced by bacteria 
themselves, and are formed through interconnecting extracellular substances that create a 
defence like matrix shell (Ciofu et al., 2015). The biofilm forms as a mechanism to protect the 
pathogen and this type of infection often follows repeated and on-going antibiotic exposure 
(Hoiby, 2011). Antibiotic concentrations of 100-1000 times more than that required for 
efficacy against the non-mucoid type are necessary to penetrate the biofilm during treatment 
(Doring et al., 2000; Ciofu et al., 2015). However, evidence has shown that the local 
concentrations of colistin achieved in the airways when nebulised are often optimal for 
efficacy against biofilm infections (Ciofu et al., 2015).  
The mucoid category of infection provides an explanation as to how the organism is able to 
outlast and endure in the airways of CF patients for numerous years despite the patient’s 
immune response and exposure to antibiotic therapy (Hoiby, 2011; Dalhoff, 2014). Chronic 
mucoid P. aeruginosa infection of the lungs in CF is similarly categorised to that of a type III 
hypersensitivity reaction whereby the large inflammatory response generated leads to 
profuse amounts of neutrophil production and the resultant decay causes the formation of 
large pus zones around the incessant bacteria which can end in total obstruction of the 
bronchi, bronchioles and alveoli ensuing irreversible lung tissue damage (Doring et al., 2000; 
Ciofu et al., 2015).  
A  study including 146 CF patients demonstrated a 40- month mean duration from diagnosis 
of CF to first P. aeruginosa isolation in the lungs with initial onset at increased age (> 2 years) 
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recognised as an independent factor for risk of development of chronic colonization of P. 
aeruginosa (Emiralioglu et al., 2016). Various antibiotic regimens can be used to eliminate the 
initial P. aeruginosa infection with median relapse periods ranging from 8-18 months 
(Emiralioglu et al., 2016). Although the ideal therapeutic options and duration of treatment 
have not yet been concluded (Emiralioglu et al., 2016), nebulised colistin is a well-established 
therapeutic agent for the early eradication of initial P. aeruginosa colonization, treatment of 
acute P. aeruginosa exacerbations and maintenance therapy for chronic infections in CF 
(Doring et al., 2000; Beringer, 2001; Michalopoulos et al., 2005). Early therapy has also been 
shown to delay the onset of chronic infection and generally improve the patient’s health 
status (Beringer, 2001; Emiralioglu et al., 2016). Mayer-Hamblett et al. (2015) showed that in 
those patients in which early eradication of P. aeruginosa is sustained, time to infection 
relapse and chronic infection is prolonged compared to those patients who are unable to 
achieve early eradication of the organism; although the study could not establish a difference 
in the improvement of lung function between both patient sets. 
 
1.9.1.  Aerosolised colistin dosing and duration of therapy for cystic fibrosis patients 
The PK of aerosolised colistin has not been vigorously established since the large drug 
particles get trapped within respiratory secretions. Absorption rates are reliant on numerous 
factors such as respiratory secretion volumes and mechanical factors which also postpone 
drug elimination (Ratjen et al., 2006; Bos et al., 2017). Delayed drug elimination may be 
advantageous since the antibiotic exposure time at the target sight may be favourably 
extended allowing for the additional conversion to active colistin (Ratjen et al., 2006; Yapa et 
al., 2014). Although colistin has been shown to be superior to other antibiotics in anaerobic 
conditions, data is conflicting with regards to the PK of aerosolised colistin due to different 
study methods used and as such, results should be interpreted with caution (Dalhoff, 2014; 
Bos et al., 2017). Also important to consider, mainstream clinical studies often determine 
efficacy by defining clinical cure and organism suppression which is difficult to attain in CF 
patients since once chronic infection is established, eradication of P. aeruginosa is impossible 
(Emiralioglu et al., 2016). Alternative outcome measures for these patients should include 
enhanced lung function and decreased bacterial density (Dalhoff, 2014).  
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Ratjen and colleagues (2006), aimed to establish the PK of colistin following an inhaled dose 
of 2 MU in 30 CF patients. The study reiterated the minimal systemic concentrations of colistin 
achieved following inhaled therapy with only 1.3% of the dose detected in the urine of study 
patients. Peak sputum concentrations were achieved one hour after the inhaled dose. 
Extremely high drug concentrations with MIC values ten times greater than international 
colistin breakpoints were reflected and maintained above the MIC value for at least eight 
hours post dose administration. As a consequence of these findings, a twice a day dosing 
regimen was recommended (Ratjen et al., 2006). Yapa et al. (2014), aimed to establish the PK 
of inhaled colistin in six patients with CF. Results of this study were similar to those of Ratjen 
et al. (2006) and demonstrated the advantages of inhaled drug delivery in achieving 
concentrations efficacious against P. aeruginosa strains with high MIC’s (Yapa et al., 2014). A 
randomised clinical trial conducted by Hodson et al. (2002) compared the outcomes of 
inhaled colistin versus tobramycin in CF patients with chronic P. aeruginosa infection. This 
study found that nebulised colistin significantly reduced the prevalence of P. aeruginosa in 
sputum, however, it did not improve or restore lung function (measured as a change in the 
study populations forced expiratory volume (FEV) which tobramycin was able to achieve 
(Hodson et al., 2002). In contrast, a multi-centre study comparing inhaled dry powder colistin 
to tobramycin nebulized solution showed colistin to be non-inferior to tobramycin in terms 
of improvement in lung function (Schuster et al., 2013).   
A 2011 Cochrane review on inhaled antibiotic therapy in CF concluded that a true meta-
analysis to determine the superiority between colistin and tobramycin is impossible due to 
the large variation in study designs but recommended inhaled therapy for CF patients to 
improve lung function and prevent infection exacerbations (Ryan et al., 2011). However, a 
network meta-analysis on this matter concluded that all available inhaled antibiotic agents 
for CF have comparable efficacy with a slight advantage of tobramycin over colistin and 
aztreonam (Littlewood et al., 2012). Members of the pulmonary clinical practice guidelines 
committee established by the United States CF foundation, believe that evidence relating to 
the efficacy of inhaled antibiotics other than tobramycin in the treatment of CF patients was 
insufficient to assess appropriate outcomes due to the limited number of studies available 
(Flume et al., 2007; Mogayzel et al., 2013). Due to the conflicting literature, there is 
inadequate evidence to conclusively support the recommendation of one antibiotic regimen 
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for the treatment of P. aeruginosa (Langan et al., 2015). This was reiterated by another 
Cochrane review conducted recently which was still inconclusive as to the appropriate 
antibiotic regimen to be used in CF to eradicate P. aeruginosa infections and improve 
associated morbidity and mortality (Langton and Smyth., 2017).  
Although general consensus is yet to be established, recent evidence in the literature 
supports inhaled and adjunctive IV therapy is recommended for the treatment of acute MDR 
P. aeruginosa exacerbations in CF. Suggested combinations include cephalosporins or 
carbapenems (IV) along with inhaled tobramycin or colistin for a duration of 14 days in order 
to optimise survival and prevent lung function decline (Antoniou and Elston, 2016; Elborn, 
2016).  
According to the limited PK studies conducted on inhaled colistin administration in CF 
patients, the recommended appropriate dosing strategy is 2 MU given in 12 hourly intervals 
(Ratjen et al, 2006; Yapa et al., 2014). In addition, the South African CF Association published 
a CF consensus guideline in 2007 which also supports the 2 MU 12 hourly colistin dosing 
strategy for these patients (SACFA, 2007). 
 
 
1.10.  Colistin use in lower respiratory tract infections and ventilator associated 
pneumonia 
Pneumonia, an infection of the lung tissue, is a serious illness that causes millions of 
admissions into hospitals each year and is associated with high morbidity and poor patient 
outcomes. Many patients develop pneumonia due to common community acquired 
pathogens, however, nosocomial pneumonias are problematic to treat and those acquired as 
a result of mechanical ventilation (VAP) can be even more detrimental to patient prognosis 
(Tumbarello et al., 2013).  For critically ill patients in high level care units with such LRTI’s, 
Gram-negative organisms account for approximately 65% of cases (Wenzler et al., 2016). Due 
to the steady increased prevalence of MDR and XDR Gram-negative organisms in the hospital 
setting colistin has become an appropriate treatment option for these infections as salvage 
therapy, however consensus on the appropriate use of inhaled colistin for this patient 
population is still yet to be established (Kofteridis et al., 2010).  
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1.10.1.  Adjunctive (dual) versus mono-therapy of aerosolised colistin in lower 
respiratory tract infections. 
In general, it is thought that aerosolised colistin should be used as adjunctive therapy to IV 
colistin for the treatment of serious MDR Gram-negative LRTI’s (Kofteridis et al., 2010; 
Wenzler et al., 2016) This recommendation follows the consideration that lung tissue 
concentrations of colistin after IV administration are low (Li et al., 2006) and studies have 
shown that high concentrations of colistin are achieved in sputum and bronchial secretions 
following aerosolised colistin administration (Michalopoulos and Papadakis, 2010). These 
concentrations have been shown to sustain for 8-12 hours in the lung tissue of most patients 
following inhalation (Michalopoulos and Papadakis, 2010). As such, the practice of concurrent 
IV and inhaled colistin is considered most appropriate for this subset of patients in order to 
achieve best possible outcomes; however, evidence to support this approach has been 
limited.   
Michalopoulos et al. (2008), evaluated 60 VAP patients who received inhaled colistin, 57 of 
which were in combination with IV colistin or other antibiotic agents. The findings revealed 
that 83.3% of patients achieved clinical or microbiological resolution and concluded that 
inhaled colistin may be considered as adjunctive therapy for VAP patients. However, it did not 
directly assess the impact of inhaled colistin with IV colistin compared to other IV antibiotics 
(Michalopoulos et al., 2008). A randomised control trial conducted by Rattanaumpawan et al. 
(2010), aimed to establish if aerosolised colistin as adjunctive therapy for the treatment of 
MDR Gram-negative VAP was safe and advantageous. Results of 51 patients who received 
inhaled colistin with other systemic antibiotics were compared to 49 patients who received 
inhaled sterile normal saline solution with other systemic antibiotics. Although the study 
could not establish an advantageous outcome of inhaled colistin over the placebo, it did 
reveal that the duration of systemic antibiotics of those patients who received inhaled colistin 
was reduced by two days (Rattanaumpawan et al., 2010).   
Kofteridis and colleagues (2010), undertook a matched case control study comparing the 
outcomes of nebulised and IV colistin to IV colistin alone (43 patients in each treatment arm) 
for the treatment of VAP. The study could not establish any clinical, microbiological or 
mortality benefit with the addition of aerosolised colistin to IV colistin therapy.  Similar 
findings were also demonstrated by Demirdal et al. (2016) and Gu et al. (2014). Tumbarello 
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et al. (2013), found no improvement in ICU length of stay or mortality comparing aerosolised 
colistin in combination with IV colistin to colistin monotherapy. However, the study did find 
improved clinical cure in patients treated with colistin dual therapy regimens. In addition, the 
length of mechanical ventilation in patients who received adjunctive inhaled colistin was 
reduced by four days (Tumbarello et al., 2013). Korbila et al. (2010), found that the use of 
nebulised colistin combined with IV colistin to be an independent factor of VAP cure 
compared to IV only treatment. These studies all involved relatively small patient cohorts and 
none  demonstrated improvement in overall mortality between the two patient groups 
(Kofteridis et al., 2010; Korbila et al., 2010; Tumbarello et al., 2013; Gu et al., 2014; Demirdal 
et al., 2016). 
However, a systematic review and meta-analysis conducted by Liu et al. (2015), aimed to 
clarify the incongruent findings of the preceding studies and establish the efficacy and safety 
of combined aerosolised and IV colistin versus IV colistin alone for the treatment of MDR 
Gram-negative nosocomial pneumonia. With a pooled sample of 672 patients, significance 
and improvement was established in patients who received both IV and inhaled colistin in 
terms of clinical cure, microbiological cure and all-cause mortality with no evidence of 
additional side effects (Liu et al., 2015). This study established for the first time the clinical 
benefits and improved outcomes of the dual therapy colistin strategy for nosocomial LRTI’s 
(Liu et al., 2015). Valachis et al. (2015), also conducted a systematic review and meta-analysis, 
the findings of which were similar to those of Liu et al. (2015). However, in the analysis, 
improvement in infection related mortality could be established but not in overall mortality 
between patients receiving inhaled and IV colistin compared to IV colistin monotherapy 
(Valachis et al., 2015).  
Tulli and colleagues (2017), found that therapeutic regimes including colistin either inhaled 
or systemic for the management of VAP did not demonstrate inferior outcomes when 
compared to standard treatment regimens. Vardakas et al. (2017), conducted a systematic 
review and meta-analysis of 373 patients to establish the efficacy and safety of aerosolised 
colistin alone (without concomitant IV therapy) for the treatment of MDR nosocomial 
pneumonia since the combined therapy may lead to increased healthcare costs and systemic 
related toxicities.  The review revealed that no difference in mortality could be established 
and microbiological and clinical cure was as effective using inhaled colistin monotherapy. Jang 
30 
 
et al. (2017), and other previous studies (Kwa et al., 2005; Lu et al., 2012), demonstrated 
similar findings concluding that aerosolised colistin on its own represents a valid alternative 
for the treatment and management of MDR VAP. However, Gutierrez-Pizarraya et al. (2017), 
cautioned against this strategy since the risk of bacterial systemic dissemination to cause 
bacteraemia in critically ill patients with nosocomial pneumonia is high and recommended 
that aerosolised colistin be administered in combination with IV antibiotics to ensure clinical 
and microbiological cure for these fatal infections.     
In contrast, however, Rello et al. (2017) issued an ESCMID position paper on the use of 
aerosolised antibiotics for LRTI’s in mechanically ventilated patients. The panel concluded 
against recommending the utilization of inhaled antibiotics for the treatment of VAP due to 
the lack of robust supporting evidence and the rates of related respiratory complications 
when antibiotics are administered through this route (Rello et al., 2017). Although recognised 
as common practice, the utilization of aerosolised colistin alone without concomitant IV 
therapy was also not recommended whilst the use of dual route colistin therapy was 
cautioned due to patient safety concerns (Rello et al., 2017). As such, consensus on adjunctive 
IV colistin with inhaled colistin versus monotherapy of inhaled colistin with or without IV 
therapy of other antibiotics for the treatment of nosocomial pneumonia in general is lacking.  
 
1.11.  Antibiotic resistance in South Africa 
In an editorial entitled “Wake up, South Africa! The antibiotic horse has bolted,” it was stated 
that South Africa has become reliant on colistin as a final option for the treatment of MDR 
Gram-negative infections including the CPE labeling it as a “home grown” multifaceted 
problem (Mendelson et al., 2012). Furthermore, carbapenem susceptibility was shown to 
decrease by 18% over a four year period in South African public sector hospitals and in 2011, 
13.6% of blood stream infections caused by A. baumanii were resistant to colistin in a public 
Cape Town hospital (Visser-Kift et al., 2014). A point prevalence study conducted locally by 
Paruk et al. (2012), evaluated antibiotic prescription practices in the intensive care units (ICU) 
of both public and private sector hospitals in five provinces. This study found that unsuitable 
antibiotics were initiated in over 50% of patients reviewed and 72% of these patients received 
antibiotic therapy for an inappropriate duration. Alarmingly, van Boeckel et al. (2014) noted 
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that antibiotic consumption increased dis-proportionately to population growth during 2000-
2010 in the BRICS countries, of which South Africa is one. The problems experienced currently 
with drug-resistant tuberculosis and non-albicans Candida infections, which are resistant to 
first line antifungal therapy, further enhances the crisis South Africa is facing with MDR 
organisms (Mendelson and Matsoso, 2014). In addition, the CPE organisms have been 
detected across the country in most cities and towns such as Johannesburg, Pretoria, Cape 
Town, Bloemfontein, Port Elizabeth and Witbank (Brink et al., 2012).  
 
The current state of antibiotic resistance in South Africa and its impact on public health was 
summarized by Sekyere (2016) whereby evaluation of carbapenem resistance amongst 
Enterobacteriaceae over a six year period revealed detection of over 2300 isolates with 
increased prevalence in Gauteng province followed by KwaZulu-Natal. The NDM-1 and OXA-
48 carbapenemases were most abundantly identified. Investigations of these cases revealed 
that the majority of patients had no travel history outside of the country which may indicate 
that these enzymes emerged as a direct result from increased carbapenem use and exposure 
locally. In South Africa, an exponential increase in carbapenem utilization occurred between 
2009 and 2011 as a consequence of rising rates of ESBL producing Enterobacteriaceae 
infections. This in turn may have contributed to the risk of selective pressure for the 
emergence of CPE in the country (Sekyere, 2016).  
 
1.12.  The emergence of colistin resistance 
In recent years an alarming increase in documented reports have emerged worldwide 
indicating instances of colistin-resistance in Gram-negative pathogens (Jayol et al., 2014; 
Coetzee et al., 2016). The first reports of colistin resistant organisms were described in 1999 
from the Czech Republic and these remained isolated and sporadic until very recently 
(Coetzee et al., 2016). Locally, Brink et al. (2013) reported a case of pan-resistant OXA-181 
producing K. pnuemoniae. In such instances the consequences of MDR and pan-resistant 
organisms are dire and are associated with an increased risk of patient mortality. This is 
because there are no antibiotics available to treat these fatal infections.  
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The colistin resistant plasmid mediated mcr-1 gene was recently identified in human and 
animal samples in China (Liu et al., 2016).  Reports of this gene have since been identified in 
over 17 countries. In South Africa, detection of this gene has occurred in multiple cities 
including Johannesburg, Pretoria and Cape Town in clinical isolates from hospitalized (n=3) 
and community (n=6) patients, as well as in poultry samples (Coetzee et al., 2016). Such 
evidence further highlights the antibiotic resistant problems the country is facing (Coetzee et 
al., 2016; Al-Tawfiq et al., 2017). Since then, mcr-2 (Xavier et al., 2016) and mcr-3 (Litrup et 
al., 2017; Yin et al., 2017) colistin resistant genes have been identified suggesting the prompt 
adaptability of the resistance mechanism of this gene. The plasmid mediated mechanism of 
resistance displayed by the gene allows for the swift capability of horizontal transmission 
between and within bacterial organisms and as such many more pathogens could become 
affected in the future (Litrup et al., 2017).     
 
Brink et al. (2012) believe that “suboptimal dosing may also be a contributing factor for the 
development of resistance” and that antibiotics reserved as final options, such as colistin, 
should be dose optimized and avoided as mono-therapy administration in an attempt to 
curtail the current resistance crisis.   
 
1.13.  Antibiotic stewardship 
There are multiple factors that contribute to the crisis of antibiotic resistance thus it is naïve 
to believe that one single solution can solve the problem. However, numerous initiatives 
globally and nationally are orchestrating mechanisms in which to minimize the threat of MDR 
organisms primarily through the promotion of appropriate infection control programs and 
advocating the judicious use of antimicrobial agents through antibiotic stewardship programs 
(ASP). These initiatives are to ensure the sensible use of antibiotics and the most positive 
outcomes for patients in an attempt to decrease antimicrobial resistance; thus the primary 
goal of any antibiotic stewardship program is to improve patient care and healthcare 
outcomes (Dodds Ashley et al., 2014). Antibiotic stewardship is a colloquial term used to 
describe initiatives and interventions that can improve antibiotic prescribing practices. It 
includes the evaluation and monitoring of the appropriate drug, dose, duration and route of 
antibiotics to optimize patient safety and outcomes (File et al., 2014).   
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 International organizations including the Centre for Disease Control (CDC), and the European 
Society of Clinical Microbiology and Infectious Disease (ESCMID), as well as, locally the 
Federation of Infectious Diseases Society of South Africa (FIDSSA) and the South African 
Antibiotic Stewardship Program (SAASP) recommend antibiotic stewardship programs to 
manage organism resistance problems in all hospitals. Mendelson et al. (2012) advocated the 
“return to rational antibiotic prescribing through strong antibiotic stewardship” guided by 
specific programs for South Africa. This message is further enhanced by the ‘Best Care Always’ 
South African organization which provides guidelines relating to the implementation of 
antibiotic stewardship practices.  
 
The favorable impact of ASP initiatives internationally has demonstrated reductions in 
antibiotic costs, antibiotic resistance, hospital length of stay and, unintended consequences 
of antibiotic therapy such as Clostridium difficile (Goff et al., 2012). Such stewardship 
interventions include: formulary restriction, IV to oral therapy conversion, prospective audit 
and feedback methodologies pertaining to, amongst others, dose, duration, compliance to 
obtaining a culture prior to antibiotic administration and, streamlining of antibiotic therapy 
following such results (Goff et al., 2012; File et al., 2014). Additional stewardship processes 
include: therapeutic drug monitoring of numerous antibiotics, vaccination campaigns, 
automatic stop orders and antibiotic batching. Many of the initiatives described are led by 
infectious disease specialist physicians and pharmacists, however, such models are difficult 
to replicate in the South African setting as such expertise are limited (Brink et al., 2016).  
 
In order to adapt these initiatives to the South African context, existing resources such as 
pharmacists and nurses are ideally placed to develop, and execute antibiotic stewardship 
initiatives in healthcare settings (Schellack et al., 2016). The collective impact of hospital 
pharmacists and their critical role as pivotal members of multi-disciplinary teams in various 
antibiotic stewardship initiatives has been demonstrated recently across a private hospital 
network in South Africa (Table 1.3). As is evident from Table 1.3, the general pharmacist can 
lead and make a difference in antibiotic stewardship initiatives which have a direct and 
positive impact on overall patient care. Although much of this work occurred in the South 
African private hospital sector, it is applicable and can be adapted for implementation in 
public hospitals too, with appropriate institutional support and allocated ‘protected 
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stewardship time,’ as these principles are universal and applicable to all settings where 
antibiotics are prescribed. Boyles et al. (2013) showed that the implementation of a dedicated 
antibiotic prescription chart and weekly antibiotic stewardship ward rounds reduced 
antibiotic consumption and cost without impacting readmission rates and patient mortality 
in a Western Cape public hospital.  
 
Table 1.3. The hospital pharmacists impact in various antibiotic stewardship initiatives in 
South African private hospitals 
Antibiotic Stewardship 
Initiative 
Pharmacists Impact 
Implementation of a “hang 
time” intervention to improve 
the time from antibiotic 
prescription to administration 
in hospital settings (Messina et 
al., 2015) 
With every hour in delay of antibiotic administration 
mortality can increase by 7.6% in patients with sepsis and 
septic shock (Kumar et al., 2006). Therefore, ensuring the 
timely administration of antimicrobials is critical in the 
management of patients with infections. 
Implementation of a pharmacist driven initiative to 
ensure the prompt administration of antibiotics within 
one hour following prescription (commonly known as 
antibiotic ‘hang time’) significantly increased compliance 
to a ‘hang time’ by 47%. 
Implementation of “low – 
hanging fruit” stewardship 
interventions to decrease 
antibiotic consumption (Brink 
et al., 2016) 
Pharmacists undertook a prospective audit and feedback 
method to implement and monitor five foundational 
stewardship interventions including: Duration of 
antibiotics greater than seven and 14 days; ensuring a 
culture is taken prior to the commencement of antibiotic 
therapy; inappropriate duplicate antibiotic cover and the 
concurrent co-administration of more than four 
antibiotics. An intervention was required for one in every 
15 prescriptions and overall antibiotic consumption 
significantly decreased over the study period by 18%. 
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Antibiotic Stewardship 
Initiative 
Pharmacists Impact 
Improving compliance to 
surgical prophylaxis guidelines 
to decrease surgical site 
infections (Brink et al., 2016) 
Appropriate peri-operative antibiotic prophylaxis is 
critical in minimizing the risk of surgical site infections 
(SSI) post-operatively. Pharmacists undertook to 
improve compliance to a bundle of four antibiotic 
prophylactic measures including: appropriate agent, 
appropriate dose, appropriate time of administration 
and appropriate duration of prophylaxis based on a 
recommended peer reviewed guideline mainly for 
caesarean sections and orthopedic surgeries. There was 
a significant improvement in compliance with all process 
measures and overall bundle compliance significantly 
increased by 24.7%. This had a direct impact on the SSI 
rate which decreased by 19.7%.  
 
These proven strategies are important processes that can contribute to the appropriate use 
of antibiotics and the limitation of antibiotic resistance in low to middle income countries 
such as South Africa.  
 
1.13.1.  Obtaining microbiological cultures as a fundamental stewardship tenet 
One of the foundational principles of antibiotic prescribing includes obtaining an accurate 
infectious disease diagnosis. This is done through: a) establishing the site of infection, b) 
understanding the co-morbidities of the patient and, c) establishing a microbiological 
diagnosis (Leekha et al., 2011). The effective management of resolving infectious diseases 
relies heavily on isolating the specific organism or pathogen that may be causing the illness. 
In order to optimize microbiological diagnoses, specimens should be collected timeously, 
appropriately minimising contamination risks and, prior to the initiation of antibiotic therapy, 
to obtain an accurate result of the infecting organism (Leekha et al., 2011). The practice of 
performing microbiological cultures prior to the administration of antibiotic therapy and their 
corresponding results also form the foundation of antibiotic stewardship since antibiotic 
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therapy can then be tailored to the most suitable, narrowest spectrum agent according to the 
identified pathogen. This then attempts to minimise the patients’ exposure to broad-
spectrum antibiotic therapy in an effort to reduce the selection of antibiotic resistant 
organisms (Dellit et al., 2007).  
In South Africa, it remains the responsibility of the prescriber to request and order a culture 
to be taken for the patient.  
 
1.13.2.  Antibiotic de-escalation as a fundamental stewardship tenet 
De-escalation is defined as the “reduction on the spectrum of administered antibiotics 
through the discontinuation of antibiotics providing activity against non-pathogenic 
organisms, discontinuation of antibiotics with similar activity or switching to an agent with 
narrower spectrum” (Garnacho-Montero et al., 2015). De-escalation following knowledge of 
the causative organism and its sensitivity profile is a fundamental component of an ASP  as it 
limits exposure to broad-spectrum therapy and helps to tailor empiric treatment thus aiming 
to minimise antibiotic resistance risks. The practice of de-escalation has been shown not to 
influence patient outcomes negatively and also shorten durations of therapy (Lew et al., 2015; 
Garancho-Montero et al., 2015) dispelling the myth that long durations of broad-spectrum 
therapy render more favourable outcomes.  
The uniqueness of this colistin utilization study is that it is the first of its kind from South 
Africa, conducted across multiple hospitals, and including a reasonably large sample of 
patients. It also evaluates the compliance to locally available colistin dosing guidelines and 
reviews the utilization of colistin in relation to antibiotic stewardship principles and 
parameters.  
 
1.14.  Rationale of study 
Many unanswered questions regarding colistin use including the appropriate dosing schedule, 
duration and combination of treatment exist in the literature. This highlights the importance 
of establishing a baseline of how this drug is prescribed in clinical practice and as such the 
need for a local utilization review is evident. To the best of my knowledge, scientific peer 
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reviewed reports regarding how and why colistin is used in South Africa are unavailable and 
compliance to current dosing guidelines is unknown. Establishing this is therefore an essential 
step forward in elevating the stewardship processes in South African hospitals for this last 
resort antibiotic agent.  
 
1.15.  Research aims and objectives  
The aim of this study was to retrospectively evaluate the use of colistin and consider the 
clinical outcomes of patients while on colistin in four private sector South African hospitals; 
in order to establish a baseline of how the drug is used and provide insight to enhance the 
appropriate use of this antibiotic in the future.  
 
The objectives of this study were therefore; 
2. To ascertain colistin utilization including: dose, dose frequency, route of administration 
and duration of treatment. 
3. To ascertain which were the most prevalent infecting micro-organisms and source of 
infections that necessitated the use of colistin.  
4. To establish if appropriate antimicrobial stewardship principles are practiced during 
colistin therapy. 
5. To establish patient outcomes while on colistin therapy including effects on renal 
function, hospital length of stay and overall in-hospital mortality. 
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CHAPTER TWO 
 STUDY METHODOLOGY 
 
 
2.1. Study design 
This study was a multi-center retrospective electronic record review conducted to investigate 
the appropriateness of colistin utilization in adult patients across four private sector hospitals 
in South Africa (including two hospitals each in Johannesburg and Pretoria). The study was 
conducted over a ten month period from 1 September 2015- 30 June 2016. 
 
2.2. Hospital selection 
The four participating hospital sites were purposefully selected for this study as they are large 
and highly specialized referral centers of excellence for complicated medical conditions. In 
addition, the four hospitals were identified as high colistin usage hospitals by the hospital 
group as together they accounted for over 70% of the groups’ overall consumption of colistin. 
Furthermore, information on colistin use was readily available from these hospitals as they 
had already transitioned onto the electronic antibiotic and infection surveillance system 
namely Bluebird® in early 2015.  
 
For the purposes of this dissertation and any related publications, the hospital names will 
remain anonymous in order to comply with the study approval requirements set out by the 
study ethics approval and hospital group research committee approval. This is also to protect 
the hospitals from any positive or negative feedback that may result from the study findings. 
Each hospital was able to request their results and the information provided does not reflect 
on the results of the other hospitals that participated in this study. When publishing the 
results of this study, the hospitals are referred to as Hospital 1, 2, 3 and 4.  
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2.2.1.  Preliminary analysis of colistin utilization 
Preliminary baseline data analysis indicated that 325 patients received colistin therapy in the 
four selected hospitals over a twelve month period in 2014 (Hospital group antibiotic 
utilization report, January 2015) thus indicating that a substantial number of patients could 
potentially be reviewed and incorporated in the study through the inclusion of these 
hospitals. Hospital one is a 346-bed, level one trauma hospital situated in Johannesburg which 
offers expertise in all medical disciplines except for maternity and pediatrics. Hospital two is 
a 222-bed Johannesburg based hospital with expertise in trauma and cardiology. Hospital 
three is a 358-bed, specialized healthcare center of excellence in Pretoria for trauma, general 
medicine, surgery, critical care and hematologic oncology. Hospital four, also in Pretoria, is a 
470-bed institution with a wide variety of medical specialties including general surgery, 
cardiology and oncology. Table 2.1 shows the number of specialized care beds per site and 
the total number of patients on colistin at the time of preliminary baseline data analysis (1 
January 2014 - 31 December 2014). 
 
Table 2.1. Number of specialized care beds and number of patients on colistin therapy at 
the four selected private hospitals (data collected 2014) 
Hospital 
Number of adult ICU 
beds 
Number of adult 
high care beds 
Total number of 
patients on colistin* 
Hospital 1 66 29 114 
Hospital 2 32 8 16 
Hospital 3 35 29 170 
Hospital 4 65 33 25 
Total 198 99 325 
*This data comprises of all patients, adult and pediatric, for which colistin was dispensed 
including all possible routes of administration (intravenous, aerosolised and irrigation).  
 
2.2.2. Antibiotic prescribing in the private healthcare sector of South Africa 
It is important to note that in South Africa, private healthcare clinicians consult their services 
to this sector and are not employees of the hospital. Due to the autonomous nature of the 
private sector and the consequential inability by private hospital groups to be prescriptive in 
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prescribing practices required from the private practitioners; no restrictions or guidelines 
have been imposed for antimicrobial prescribing in private hospitals to date. The hospital 
group in which this study was conducted has a medication formulary which in itself is all 
inclusive and contains all antibiotics available on the South African market. In contrast to the 
South African public sector hospital system, private practitioners are also not bound to 
prescribe only according to the National Department of Health (NDoH) Standard Treatment 
Guidelines (STG’s). As a result of the aforementioned factors, a true reflection of the 
prescribing of colistin could be determined for this study as it would not be influenced or 
biased by hospital or group imposed protocols or formularies. 
 
2.3. Sample selection 
2.3.1. Inclusion criteria  
Adult patients (over the age of 18 years) at the participating hospitals who were deemed to 
have received colistin therapy as a result of the product being dispensed, and thus billed to 
the patients profile, via the IV and aerosolised routes of administration, were included in the 
study.  
 
2.3.2.  Exclusion criteria  
Pediatric and neonatal patients and those receiving colistin via an alternative route of 
administration were excluded from the study. These exclusions were made because limited 
evidence exists regarding the appropriate use of colistin in the pediatric and neonatal patient 
populations, since safety and efficacy studies have not been conducted in these patient 
categories.  Nor do approved recommendations for other routes of administrations, such as 
irrigations, exist. These practices are mostly off label and therefore were not included in the 
study. Patients who were dispensed and billed colistin but whose profiles were not 
appropriately updated on the Bluebird® electronic system and those with a large amount of 
missing electronic data were also excluded.  
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2.4. Ethical considerations 
The necessary approvals were obtained from the individual participating hospitals and the 
hospital groups’ research committee (Appendix B) and ethical clearance (M150404) was 
granted by the University of the Witwatersrand Human Research Ethics Committee (Appendix 
C) prior to the commencement of data collection.  
 
2.5. The Bluebird® system and identification of patients  
The retrospective electronic record review of adult patients on colistin treatment was 
conducted using the Bluebird® system. This web based electronic system integrates 
laboratory data from the main private laboratories, as well as, hospital medication dispensing 
data and the patient’s admission master file (Figure 2.1). The electronic patient record derived 
from the system allowed for the identification of patient’s in each hospital to whom colistin 
had been dispensed, the monitoring of laboratory culture results, their drug prescription data, 
hospital movements and overall in-hospital outcome. All aspects of a patients’ antibiotic 
therapy were captured onto the Bluebird® system by local hospital ward pharmacists. Clinical 
biochemistry, hematology and serology results, organism culture results and corresponding 
sensitivity profiles were also available electronically on the system for review. The researcher 
was granted access to the Bluebird® system of the four participating hospitals for the duration 
of the study period by the hospital group.  
 
Figure 2.1. The integration processes of the Bluebird® electronic surveillance system used 
to retrospectively identify and evaluate records of patients on colistin therapy.  
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2.6.  Data collected of patients prescribed colistin 
The data described in Table 2.2 were collected per study patient on a standardized data 
collection template (Appendix D). Data was manually collected to include all the required 
demographic, clinical and therapeutic data for each patient on colistin (according to the study 
inclusion criteria) following review of patient records on the Bluebird® system. Findings were 
entered onto a spreadsheet using Microsoft® Excel for statistical analysis and qualitative 
interpretation. Data collection was coded to ensure patient and hospital confidentiality and 
any traceable information was kept electronically in a password protected folder.  
 
Table 2.2. Data collected for patients prescribed colistin in four private sector hospitals in 
South Africa 
Data indicator Reason required for the study 
Hospital identification code To categorize patients according to hospitals for 
comparison of colistin prescription between hospitals. 
Unique patient study number To link the manually completed patient data collection 
forms (Appendix D) to the Bluebird® system for follow 
up of patient information throughout the hospital 
length of stay.  
Date To document the date of record review 
commencement of the study patient by the researcher. 
Ward To document the ward in which the study patient 
commenced colistin therapy for comparison of 
prescribing between high level care units and general 
wards (if any). 
Patient gender To document the gender of patients included in the 
study for patient demographic information. 
Patient Age To document the age of study patients to determine the 
age demographic range of adult patients requiring 
colistin therapy.   
Patient weight Weight is a variable required for the calculation of 
creatinine clearance to determine the drugs’ effect on 
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Data indicator Reason required for the study 
patient renal function pre and post colistin exposure 
and was recorded for this purpose.  
Patient admitting diagnosis To establish the primary reason for study patients’ 
hospital admission.  
Acute Physiology and Chronic 
Health Evaluation (APACHE II) 
score 
To measure the severity of disease of study patients 
admitted to intensive care units. 
The indication for 
commencement of colistin 
therapy 
To determine the reason colistin therapy was required 
and prescribed. This was categorized according to the 
following:  
a) empiric therapy (if no evidence of an MDR or 
XDR Gram-negative organism was found prior to 
or during the course of treatment), 
b) directed therapy (infection with an MDR or XDR 
organism of known sensitivity),  
c) salvage therapy (failure of an alternative 
treatment where colistin was used as escalation 
therapy), 
d) No clinical reason (if there was no evidence to 
indicate a reason for colistin therapy at any 
point during the patients hospitalization 
including the review of sepsis markers deemed 
to be normal), 
e) Other (if the reason for colistin therapy did not 
fit any of the above mentioned categories). 
Start date of colistin therapy To record the date in which colistin therapy first 
commenced in order to assist in establishing total 
treatment days of colistin per study patient.  
End date of colistin therapy To record the date in which colistin therapy terminated 
(date of last colistin dose administered) in order to 
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Data indicator Reason required for the study 
assist in establishing total treatment days of colistin per 
study patient. 
Total days of colistin therapy  To determine the number of treatment days of colistin 
therapy per patient. The first day of colistin 
administration was counted as day one of therapy.   
Route of colistin administration To establish if colistin was prescribed either IV or via 
nebulisation in order to categorize patients according 
to route of administration.  
The prescription of a colistin 
loading dose 
To establish if a colistin loading dose was prescribed as 
is recommended best practice by local colistin dosing 
guidelines (Labuschagne et al., 2016 ; Visser-Kift et al., 
2014) 
Actual colistin loading dose 
prescribed 
To record the actual colistin loading dose in million 
international units (MU) prescribed per patient. 
Colistin maintenance dose and 
frequency prescribed 
To record the maintenance dose prescribed per patient 
including the dose (MU) and the frequency of 
administration prescribed (hourly intervals of colistin 
administration).  
First or repeat course of colistin To establish if this was the first exposure to colistin for 
the patient or not.  
Compliance to antibiotic ‘hang 
time’ 
This data was recorded to establish if colistin was 
administered within one hour following prescription as 
is recommended for patients with sepsis (Kumar et al., 
2006)   
Laboratory cultures taken To determine if an appropriate culture was taken prior 
to the commencement of colistin therapy in order to 
identify the possible causative organism of the 
infection. 
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Data indicator Reason required for the study 
Culture specimen type To establish which clinical specimens were tested for 
possible organism growth. These were categorized as 
follows:  
- Urine 
- Blood 
- Trachael aspirate 
- Sputum 
- Other  
Infecting organism cultured To record and review the results of the organism 
identified following laboratory and microbiological 
review necessitating the use of colistin. This data was 
established from the laboratory report.  
Organism sensitivity profile To determine the resistance patterns of the organisms 
cultured and to establish appropriate drug-bug match 
(e.g.: if alternative therapeutic options were available 
to treat the organism or if colistin was the only option).  
Minimum inhibitory 
concentration (MIC) 
To document the MIC of antibiotics for the infecting 
organism identified in the study (when available) to 
provide further insight into the severity of resistance of 
the organism.  
Other co-prescribed antibiotics To record other Gram-negative antibiotics prescribed 
along with colistin since colistin monotherapy is not 
considered best practice (Richards et al., 2015) 
Serum Creatinine (SCr) prior to 
and post colistin treatment  
Used to establish the patient’s creatinine clearance on 
the first and last days of colistin therapy in order to 
determine the antibiotics effect on renal function per 
patient (if any). This data was recorded from the 
serology test results from laboratory reports.  
The Cockcroft-Gault Equation was used to establish 
this:  
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Data indicator Reason required for the study 
(((140-age in years) x (wt in kg)) x 1.23) / (serum 
creatinine in micromole/L)   
- A published South African colistin dosing guideline 
made dosing recommendations according to renal 
function based on creatinine clearance criteria. 
Therefore, this variable was required to establish 
colistin dosing compliance to this guideline 
(Labuschagne et al., 2016). 
Estimated glomerular filtration 
rate (eGFR) prior to and poste 
colistin treatment  
The eGFR was also recorded to establish the patients 
renal function on the first and last days of colistin 
treatment to determine the antibiotics effect on renal 
function per patient (if any). This data was recorded 
from the serology test results from laboratory reports.  
- Another South African colistin dosing guideline 
made dosing recommendations according to renal 
function based on eGFR criteria. Therefore, this 
variable was required to establish colistin dosing 
compliance to this guideline (Visser-Kift et al., 2014) 
De-escalation of colistin therapy  De-escalation or streamlining of antibiotic therapy 
refers to the practice of tailoring therapy from broad-
spectrum to narrow-spectrum following culture 
sensitivity results (Garnacho-Montero et al., 2015). De-
escalation practices were reviewed to determine 
compliance to this antibiotic stewardship principle.   
Choice of de-escalated antibiotic To establish which antibiotic was the agent of choice on 
occasions when therapy was de-escalated. 
Total length of stay (LOS) in the 
Intensive Care unit (ICU).  
To determine the number of days spent by each study 
patient in the ICU as a study outcome measure. 
Total LOS in hospital To determine the overall duration of hospital admission 
(including ICU and general ward stay) spent by each 
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Data indicator Reason required for the study 
study patient (measured in days) as an additional study 
outcome measure.  
Overall in-hospital patient 
outcome 
To establish if the study patients were discharged from 
the hospital or demised in hospital as a third study 
outcome measure. 
 
 
2.7. Patients 
Due to the retrospective record review nature of this study, there was no direct contact with 
patients. As such, no informed patient consent from the patient was needed and permission 
to use aggregated anonymised data for research purposes is granted as part of the hospital 
admission process. The patients’ antibiotic dosing regimens were not affected in any way by 
this study. Confidentiality of patient and hospital data has been maintained throughout and 
only cumulative data is presented, therefore, data cannot be traced back to an individual 
patient.  
 
 
2.8.  Statistical analysis  
Statistical analysis was conducted with the assistance of a statistician from the Data 
Management and Statistical Analysis (DMSA) consortium (http://www.dmsa.co.za/).  
 
2.8.1. Sample size 
Sample size was determined by the key research question to be answered.  For the 
determination of the prevalence of patients with a particular characteristic (e.g. the 
percentage of females in the study group), a sample size estimation was based on a 50% 
prevalence (worst-case in terms of sample size), 5% precision and a 95% confidence interval. 
Based on this methodology and taking this study into consideration, a sample size of 385 
patients was required.  The actual sample size of 237 patients in this study corresponds to a 
precision of 6.4% (rather than 5.0%), which is acceptable. 
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Sample size for prevalence was determined using the formula (Daniel, 1999): 
n=(Z^2 P(1-P))/d^2 
where; n=sample size, Z=Z-statistic for the chosen level of confidence, P=expected prevalence 
or proportion and, d=precision.  
 
2.8.2. Statistical methodology 
Descriptive analysis of the data was carried out as follows:  categorical variables were 
summarized by frequency and percentage tabulation, and illustrated by means of bar charts. 
Continuous variables were summarized by the mean, standard deviation, median and 
interquartile range (IQR), and their distribution illustrated by means of histograms. The Χ2 
test was used to assess the relationships between categorical variables.  Fisher’s exact test 
was used for 2 x 2 tables or where the requirements for the Χ2 test could not be met. The 
strength of the associations was measured by Cramer’s V and the phi coefficient respectively. 
The scale of interpretation used is summarized in Table 2.3. 
 
Table 2.3. Interpretation of statistical associations between categorical variables 
Statistical association strength Interpretation of association 
0.50 and above       high/strong association 
0.30 to 0.49 moderate association 
0.10 to 0.29 weak association 
below 0.10 little if any association 
 
 
The relationship between continuous and categorical variables was assessed by the t-test (or 
ANOVA for more than two categories).  Where the data did not meet the assumptions of 
these tests, a non-parametric alternative, the Wilcoxon rank sum test (or the Kruskal-Wallis 
test for more than two categories) was used. The strength of the associations was measured 
by the Cohen’s d-value for parametric tests and the r-value for the non-parametric tests. The 
scale of interpretation used is reflected in Table 2.4.  
 
 
49 
 
Table 2.4. Interpretation of statistical associations between continuous and categorical 
variables 
Statistical association strength Interpretation of association 
0.80 and above       large effect 
0.50 to 0.79 moderate effect 
0.20 to 0.49 small effect 
below 0.20 near zero effect 
 
 
The relationship between the two continuous variables was assessed by Pearson’s correlation 
coefficient. Where the data did not meet the assumptions of these tests, a non-parametric 
alternative, Spearman’s rank correlation coefficient was used.  The strength of the 
associations was measured by interpreting the absolute value of the correlation coefficient.  
The scale of interpretation used is described in Table 2.5. 
 
Table 2.5. Interpretation of statistical associations between two continuous variables 
Statistical association strength Interpretation of association 
0.50 and above       large effect 
0.3 to 0.49 moderate effect 
Below 0.3 small effect 
 
 
Data analysis was carried out using SAS® version 9.4 for Windows.  The 5% significance level 
was used.  In other words, p-values <0.05 indicate significant results. Determination of 
significance was only conducted on the results of patients who received IV colistin therapy as 
the sample size of those who received nebulized colistin was too small to render valid 
appropriate interpretations.  
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2.9.  Summary of study process 
A summary of the complete methodical process undertaken for this study is depicted in Figure 
2.2. 
 
Figure 2.2. Summary of the study process and methodology 
 
• Obtained study protocol approval. 
• Obtained ethics approval from the University’s Human Research Ethics 
Committee (medical).  
Clearance number: M150404. (Appendix C) 
• Obtained individual hospital and hospital group research office 
approval. (Appendix B) 
 
• Conducted a retrospective record review of electronic patient 
records of patients on colistin treatment according to study 
inclusion criteria.  
• Data was obtained using the Bluebird® system and recorded 
manually using Appendix D. 
• Study period: 10 months (01 September 2015- 30 June 2016). 
 
• Following completion of data collection, findings were captured 
onto Microsoft Excel® for statistical analysis and interpretation. 
• Evaluation of data and statistical analysis conducted. 
• Writing of theses chapters. 
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CHAPTER THREE 
REVIEW OF INTRAVENOUS (IV) COLISTIN UTILIZATION ACROSS FOUR PRIVATE 
SECTOR HOSPITALS IN SOUTH AFRICA 
 
 
3.1 Introduction 
A total of 237 patients on colistin therapy from the four participating hospitals during the ten 
month study period were included in this study. Of these, 89.5% (n=212) of patients received 
colistin via the IV route of administration. For the purposes of this chapter, the results of the 
colistin utilization review conducted in these patients will be discussed. The remaining 10.5% 
(n=25) of patients received aerosolised colistin, the findings of which will be discussed in the 
chapter to follow.  
 
3.2. Results  
3.2.1.  General patient demographics 
The number of patients on IV colistin contributing to the study per hospital is depicted in 
Figure 3.1. Hospital four contributed the most number of patients 55.2% (n=117) followed by 
hospital one 26.4% (n=56), hospital two 10.4% (n=22) and hospital three 8.0% (n=17). The 
majority of patients were male 56.1% (n= 119) (Figure 3.2) and 80.7% (n= 171) received 
colistin whilst in the ICU (Figure 3.3). A smaller population of patients received colistin in 
general wards 19.3% (n=41). For 82.1% (n=174) of patients, this was their first exposure to 
colistin whilst 17.9% (n=38) had previously received a course of colistin therapy during their 
hospital admission (Figure 3.4). The mean age of patients included in the study was 50.9 years 
(SD 16.6; range 18-93 years). This mean age is similar to that described in other colistin 
utilization reviews conducted (Table 1.1).   
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Figure 3.1. The number of patients per hospital on intravenous colistin therapy included in 
the study (n= 212) 
 
 
Figure 3.2. A breakdown of the number of patients on intravenous colistin therapy included 
in the study according to gender (n=212) 
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Figure 3.3. A breakdown of the number of patients on intravenous colistin therapy included 
in the study according to hospital ward location (n=212) 
 
 
Figure 3.4. A breakdown of the number of patients for which an initial colistin course versus 
repeated colistin course was prescribed during their hospital admission (n=212) 
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A breakdown of the broad categories of admission diagnosis of the patients is depicted in 
Figure 3.5. Classification of admitting diagnosis according to exact ICD 10 codes could not be 
established from the electronic record as the exact admitting diagnosis was often not 
completed, nor was there a field on the system to record ICD 10 codes and, as such, broad 
categories of disease state admitting diagnosis were used to classify patients.  All patients 
could be classified as critically ill receiving treatment in highly specialised tertiary level care 
hospitals. The most prominent of which was immune compromised, neutropenic, bone 
marrow oncology 40.1% (n=85) followed by trauma 11.3% (n=24) and blood stream infections 
7.1% (n=15). Although an initial metric of this study, the illness severity score (APACHE II) 
score could not be recorded per patient as this was not documented on the electronic patient 
record. Upon further investigation, it was determined that this score is mostly not recorded 
on paper prescription charts in hospitals but rather kept by prescribers in their personal notes 
and records. Therefore patient risk in relation to mortality or outcome could not be corrected 
for or determined. 
 
Figure 3.5. A breakdown of the number of patients per category of admitting diagnoses for 
patients included in the study on intravenous colistin (n=212) 
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The indication for colistin treatment (Figure 3.6) was mostly as directed therapy as a result of 
evidence of an infection with an MDR organism 57.1% (n=121), followed by empiric therapy 
33.5% (n=71) and salvage therapy 9.4% (n=20), the study definitions of which are described 
in Table 2.2 (Chapter 2).  
 
Figure 3.6. A depiction of the number of patients per indication for intravenous colistin 
therapy (n=212) 
 
3.2.2. Microbiological assessment 
Cultures were performed prior to the initiation of colistin therapy in all but two patients 
(Figure 3.7) thus, reflecting good compliance to this stewardship principle.  
For the remaining 99.1% of patients (n=210), a breakdown of the specimen types tested for 
possible organism identification are described in Figure 3.8. Blood cultures were the most 
frequently tested specimens 57.4% (n=120) followed by urine 9.9% (n=21), sputum 8.1% 
(n=17) and tracheal aspirates 7.1% (n=15). The assumed inappropriateness of the 1.9% (n=4) 
of patients who were prescribed colistin following a result from a CPE rectal screening swab 
should be noted, as this is not considered a clinical specimen and positive results on such a 
screen indicate colonisation and not necessarily infection (Ruppe and Andremont, 2013). The 
entire clinical overview of these cases was not known, nor could have been established form 
the limited data available of the records available, and therefore it should be considered that 
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there may have been valid reasons for the commencement of colistin albeit deemed 
empirically for these patients. 
 
Figure 3.7. The number of patients who had a culture taken prior to the initiation of colistin 
therapy (n=212)  
 
 
Figure 3.8. A breakdown of the number of patients and the various specimen types tested 
in patients who had cultures taken (n=210) 
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The prevalence of the various organisms identified is shown in Figure 3.9. Klebsiella 
pneumoniae 34.2% (n=81), P. aeruginosa 24.9% (n=59) and A. baumanii 9.3% (n=22) were the 
most predominant pathogens identified necessitating the use of colistin. These organisms 
also form part of the Gram-negative cluster of the “ESKAPE” pathogens, globally recognised 
as a group of concerning pathogens that have shown to be increasing in prevalence and highly 
resistant, drastically limiting treatment options for hospitalised patients and, impacting 
negatively on patient outcomes (Boucher et al., 2009).   
For a substantial amount of patients in this study, however, no organism was identified 25.7% 
(n=54) although IV colistin therapy was still prescribed (Figure 3.9). For the remaining patients 
who were deemed to have received colistin empirically (Figure 3.6), 0.9% (n=2) did not have 
microbiological cultures performed and 7.0% (n=15) cultured an organism which was shown 
to be sensitive to antibiotic agents other than colistin. Due to the limitation of data available 
for review on the Bluebird system, in the absence of clinical notes and other clinical 
parameters including: fever, blood pressure, prescriber notes, severity of illness scores, and 
justification of prescriptions; determination of the exact reasons for empiric therapy could 
not be established.   
 
Figure 3.9. A breakdown of the number of organisms identified following laboratory culture 
results. Note that numbers do not sum to n=210 since some patients had more than one 
organism identified. 
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3.2.3 Evaluation of loading doses, maintenance doses and frequency of colistin doses 
prescribed in IV study patients 
3.2.3.1 Evaluation of colistin loading doses prescribed 
Compliance to the prescription of a loading dose was high with 93.9% (n=199) of patients 
prescribed a colistin loading dose. However, as depicted in Table 3.1, huge variation in the 
actual loading dose prescribed was noted. Therefore, of the patients who were prescribed a 
loading dose, 90.4% (n=180) received an appropriate loading dose (9-12 MU) indicating that 
9.6% (n=19) received sub-optimal loading doses. For 15.1% (n=32) of study patients, loading 
doses were either not prescribed (n=13) or were too low (n=19) indicating inappropriate 
management of this process measure for this cohort of patients.   
 
Table 3.1. Prescribed colistin loading doses for intravenous study patients (n=199) 
Loading Dose (MU) % of patients (n) 
4 1.5 (3) 
6 5.5 (11) 
8 2.5 (5) 
9 22.6 (45) 
11 0.5 (1) 
12 67.3 (134) 
 
3.2.3.2  Evaluation of colistin maintenance doses and frequency of administration  
prescribed 
Table 3.2 describes the colistin maintenance doses and frequency of administration 
prescribed for the study patients. The large variation of colistin maintenance doses prescribed 
is evident with dose ranges from 1-4.5 MU prescribed and frequencies including six, eight and 
12 hourly intervals (Table 3.2). The majority, 99.5% (n=211), of patients studied were 
prescribed colistin at the appropriate frequency of administration. However, one patient in 
this study was prescribed colistin six- hourly which should be deemed as inappropriate as it 
could contribute to elevated risks of drug induced toxicity.  
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Table 3.2. Prescribed colistin maintenance doses and frequency of administration for 
intravenous study patients (n=212) 
Maintenance 
Dose (MU) 
% of patients (n) 
Frequency of 
administration 
(hourly) 
% of patients (n) 
1 1.3 (3) 6 0.5 (1) 
1.5 6.1 (13) 8 35.9 (76) 
2 8.0 (17) 12 63.7 (135) 
2.5 0.9 (2)   
3 30.7 (65)   
4.5 52.8 (112)   
  
3.2.4 Compliance of study patients to two South African colistin dosing guidelines. 
3.2.4.1 Evaluation of the study patients compliance to the South African Society of Clinical 
pharmacy (SASOCP) colistin dosing guidelines  
Compliance of the study patients to the SASOCP colistin dosing guidelines is described in Table 
3.3. Dosing recommendations in this guideline are made according to Creatinine Clearance 
(CrCl). The Cockcroft-Gault equation was used to establish this based on the patients Serum 
creatinine (SCr), gender and weight (described in Chapter 2). Patient weight was difficult to 
obtain from the electronic record review as often this data was not recorded on the electronic 
patient profile. As such, CrCl was impossible to establish for these patients and, therefore, 
was the primary factor which contributed to the large number of patients (n=64) where 
guideline compliance could not be determined. For the remaining patients, compliance to 
prescribed colistin doses was very poor, 34.9% (74/212). Considering only those patients for 
which data was available, compliance to these guidelines was still poor at 50% (74/148). As 
such, this evaluation emphasized that not recording weight in this patient cohort is a process 
that should be targeted for improvement.  
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Table 3.3. Study patients’ compliance to the South African Society of Clinical Pharmacy 
colistin dosing guideline (Labuschagne et al., 2016) 
Guideline Recommendation 
Normal renal function Loading dose: 12 MU, then maintenance dose: 3 MU 8 
hourly or 4.5 MU 12 hourly 
CrCl* 40-60ml/min 2 MU 12 hourly 
CrCl* 10-40 ml/min 2 MU 24 hourly 
CrCl* < 10 ml/min 1.5 MU 36 hourly 
Study patients compliance to recommended dosing guidelines 
All categories of renal function Unknown*: 30.2% (n=64) 
Compliant: 34.9% (n=74) 
Non-compliant: 34.9% (n=74) 
*Contributions to unknown compliance are as a result of data not documented on records for 
variables including weight.  
 
 
A detailed evaluation of patient renal function according to CrCl categories, colistin doses 
prescribed and guideline compliance is presented in Table 3.4. This table highlights the huge 
variation in colistin doses prescribed according to the various categories of renal function for 
the patients studied and informs the poor dosing compliance demonstrated by Table 3.3.    
 
Table 3.4. Detailed evaluation of study patients renal function according to CrCl categories, 
colistin doses prescribed and guideline compliance 
 
Cr clearance 
Prior 
Loading 
Dose (MU) 
Dose 
(MU) 
Frequency 
(hrs) 
(n) Percentage 
(%) 
Compliance 
to guideline 
(Labuschagne 
et al., 2016) 
. . 2 8 2 0.94 unknown 
. . 3 8 1 0.47 unknown 
. 4 2 12 1 0.47 unknown 
. 6 1.5 12 1 0.47 unknown 
. 6 3 8 2 0.94 unknown 
. 8 3 8 4 1.89 unknown 
61 
 
Cr clearance 
Prior 
Loading 
Dose (MU) 
Dose 
(MU) 
Frequency 
(hrs) 
(n) Percentage 
(%) 
Compliance 
to guideline 
(Labuschagne 
et al., 2016) 
. 9 1.5 12 2 0.94 unknown 
. 9 3 8 7 3.3 unknown 
. 9 3 12 1 0.47 unknown 
. 9 4.5 12 2 0.94 unknown 
. 11 4.5 12 1 0.47 unknown 
. 12 1 8 1 0.47 unknown 
. 12 1.5 8 1 0.47 unknown 
. 12 3 8 3 1.42 unknown 
. 12 4.5 12 35 16.51 unknown 
10-40 . 2 8 1 0.47 no 
10-40 . 3 8 2 0.94 no 
10-40 4 2 8 1 0.47 no 
10-40 9 2 8 2 0.94 no 
10-40 9 3 8 1 0.47 no 
10-40 9 3 12 1 0.47 no 
10-40 12 1 8 1 0.47 no 
10-40 12 1.5 12 5 2.36 no 
10-40 12 2 12 2 0.94 no 
10-40 12 2.5 12 1 0.47 no 
10-40 12 3 12 1 0.47 no 
10-40 12 4.5 12 3 1.42 no 
40-60 4 3 8 1 0.47 no 
40-60 6 1 8 1 0.47 no 
40-60 6 2 8 1 0.47 no 
40-60 6 2.5 6 1 0.47 no 
40-60 9 3 8 4 1.89 no 
40-60 9 4.5 12 2 0.94 no 
40-60 12 1.5 8 1 0.47 no 
40-60 12 2 12 3 1.42 yes 
40-60 12 4.5 12 2 0.94 no 
>60 . 2 8 1 0.47 no 
>60 . 3 8 5 2.36 no 
>60 . 3 12 1 0.47 no 
>60 6 3 8 5 2.36 no 
>60 8 3 8 1 0.47 no 
>60 9 1.5 8 1 0.47 no 
>60 9 2 8 1 0.47 no 
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Cr clearance 
Prior 
Loading 
Dose (MU) 
Dose 
(MU) 
Frequency 
(hrs) 
(n) Percentage 
(%) 
Compliance 
to guideline 
(Labuschagne 
et al., 2016) 
>60 9 3 8 12 5.66 no 
>60 9 3 12 2 0.94 no 
>60 9 4.5 12 7 3.3 no 
>60 12 1.5 8 1 0.47 no 
>60 12 1.5 12 1 0.47 no 
>60 12 2 8 1 0.47 no 
>60 12 2 12 1 0.47 no 
>60 12 3 8 11 5.19 yes 
>60 12 4.5 12 60 28.3 yes 
    212 99.94  
-Unknown variable 
 
 
3.2.4.2 Evaluation of the study patients compliance to a colistin dosing guideline published 
by Visser-Kift et al., 2014 
Compliance of the study patients to the colistin dosing guideline by Visser-Kift et al. (2014) is 
described in Table 3.5. This guideline made dosing recommendations based on eGFR which is 
often easier to determine compared to CrCl as the estimation is calculated from biochemistry 
results. As such, less patient data was missing, as only four patients did not have an eGFR 
performed pre and post colistin therapy. Evaluation of colistin dosing for the remaining 
patients could be determined; however, compliance to appropriate dosing based on renal 
function was also low, 41.5% (88/212). When considering only those patients for which data 
was available, compliance to these guidelines was still poor at 42.3% (88/208).  
A detailed evaluation of patient renal function according to eGFR categories, colistin doses 
prescribed and guideline compliance is presented in Table 3.6. Variation in dosing compliance 
is again demonstrated which reiterates the poor compliance to the recommended dosing 
guideline as per Table 3.5.    
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Table 3.5. Study patient compliance to a colistin dosing guideline (Visser-Kift et al., 2014) 
Guideline recommendations 
Critically ill or severe sepsis Loading dose: 9-12 MU 
eGFR > 60 ml/min 4.5MU 12 hourly 
eGFR 30-60 ml/min 3 MU 12 hourly 
eGFR 10-30 ml/min 2 MU 12 hourly 
eGFR <10 ml/min 1 MU 12 hourly 
Study patients compliance to recommended dosing guidelines 
All categories of renal function Unknown*: 1.9% (n=4) 
Compliant: 41.5% (n=88) 
Non-compliant: 56.5% (n=120) 
*Contributions to unknown compliance are as a result of data not documented on records for 
variables including eGFR.  
 
Table 3.6. Detailed evaluation of study patients renal function according to eGFR categories, 
colistin doses prescribed and guideline compliance. 
 
GFR_Prior Loading 
Dose (MU) 
Dose 
(MU) 
Frequency 
(hrs) 
(n) Percentage 
(%) 
Compliance 
to guideline 
(Visser-Kift 
et al., 2014) 
. 9 1.5 12 1 0.47 unknown 
. 12 4.5 12 3 1.42 unknown 
<10 9 3 12 1 0.47 no 
<10 12 1.5 12 3 1.42 no 
10-30 . 3 8 2 0.94 no 
10-30 4 2 8 1 0.47 no 
10-30 6 1.5 12 1 0.47 no 
10-30 6 2.5 6 1 0.47 no 
10-30 9 2 8 1 0.47 no 
10-30 9 3 8 4 1.89 no 
10-30 9 3 12 1 0.47 no 
10-30 9 4.5 12 2 0.94 no 
10-30 12 1 8 1 0.47 no 
10-30 12 1.5 8 1 0.47 no 
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GFR_Prior Loading 
Dose (MU) 
Dose 
(MU) 
Frequency 
(hrs) 
(n) Percentage 
(%) 
Compliance 
to guideline 
(Visser-Kift 
et al., 2014) 
10-30 12 1.5 12 2 0.94 no 
10-30 12 2 12 2 0.94 yes 
10-30 12 2.5 12 1 0.47 no 
10-30 12 3 12 1 0.47 no 
10-30 12 4.5 12 2 0.94 no 
30-60 . 2 8 2 0.94 no 
30-60 4 2 12 1 0.47 no 
30-60 6 1 8 1 0.47 no 
30-60 6 2 8 1 0.47 no 
30-60 9 1.5 8 1 0.47 no 
30-60 9 1.5 12 1 0.47 no 
30-60 9 2 8 1 0.47 no 
30-60 9 3 8 6 2.83 no 
30-60 9 4.5 12 5 2.36 no 
30-60 12 1 8 1 0.47 no 
30-60 12 1.5 8 2 0.94 no 
30-60 12 1.5 12 1 0.47 no 
30-60 12 2 12 3 1.42 no 
30-60 12 3 8 2 0.94 no 
30-60 12 4.5 12 14 6.6 no 
>60 . 2 8 2 0.94 no 
>60 . 3 8 6 2.83 no 
>60 . 3 12 1 0.47 no 
>60 4 3 8 1 0.47 no 
>60 6 3 8 7 3.3 no 
>60 8 3 8 5 2.36 no 
>60 9 2 8 1 0.47 no 
>60 9 3 8 14 6.6 no 
>60 9 3 12 2 0.94 no 
>60 9 4.5 12 4 1.89 yes 
>60 11 4.5 12 1 0.47 yes 
>60 12 2 8 1 0.47 no 
>60 12 2 12 1 0.47 no 
>60 12 3 8 12 5.66 no 
>60 12 4.5 12 81 38.21 yes 
    212 99.94  
-Unknown variable 
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3.2.5 Compliance to the timely administration of colistin 
Compliance to colistin ‘hang time’ in this study was poor with 54.7% (n=116) of patients 
deemed compliant and 27.8% (n=59) non-compliant. For 17.5% (n=37), compliance was 
unknown due to missing documentation of the prescription time on the electronic record. 
Only taking into account those patients for which ‘hang time’ could be determined, overall 
compliance was 66.3% (n=116/175).  
The compliance to hang time was measured as per the data collection tool (Appendix D) as a 
simple “yes or no” and the reasons for hang time delay per patient were not available on the 
Bluebrid system nor were they recorded as part of the data collection process. As such, the 
exact reasons for the delay could not be established from this analysis.  
 
3.2.6 Combination therapy  
Combination therapy was prescribed in 98.6% (n=209) patients. For 63.7% (n=131) of the 
patients a single other antibiotic was prescribed, while 33.5% (n=70) and 3.8% (n=8) had two 
and three other antibiotics prescribed, respectively. A breakdown of the concurrently 
administered antibiotics is depicted in Figure 3.10. Meropenem was the most common co-
administered antibiotic 62.7% (n=131) followed by tigecycline 28.7% (n=60). Furthermore, 
Table 3.7 describes the number of patients and the various antibiotic combinations prescribed 
in addition to colistin therapy. In total, 31 unique combinations were prescribed for the 209 
patients who received combination therapy. All co-administered antibiotic agents, with the 
exception of rifampicin, possess Gram-negative spectrum of activity. The addition of 
meropenem is currently mostly recommended for the treatment of the CPE’s and tigecyline 
in combination for Acinetobacter spp. infections (Richards et al., 2015). The reasons for 
combination therapy with other antibiotics were not determined. It is assumed that the 
addition of these alternative agents would be an attempt by clinicians to add supplementary 
mechanisms to inhibit the growth of the MDR organisms cultured in the study patients. 
Rifampicin, a Gram- positive and tuberculosis antibiotic, has been used as a combination 
agent with colistin for its anti-biofilm activity, however, the effectiveness of this strategy has 
not been well established and is not routinely recommended (Durante-Mangoni et al., 2013). 
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Figure 3.10. A breakdown of combination agents of choice prescribed with intravenous 
colistin therapy. Note values do not add up to 100% as some patients received more than 
one agent in combination.  
 
Table 3.7. The number of patients and various antibiotic combinations prescribed in 
addition to colistin therapy (n=209). 
Antibiotic Number of Patients 
One Additional Agent 
Cefepime 1 
Doripenem 12 
Gentamicin 1 
Imipenem 17 
Meropenem 84 
Pipperacillin Tazobactam 1 
Rifampicin 3 
Tigecycline 12 
Total 131 
Two Additional Agents 
Amikacin/Doripenem 2 
Cefepime/Ertapenem 1 
Cefepime/Tigecycline 1 
Imipenem/Amikacin 1 
Imipenem/Rifampicin 1 
Imipenem/Tigecycline 8 
Meropenem/Amikacin 11 
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Antibiotic Number of Patients 
Meropenem/Cefepime 2 
Meropenem/Doripenem 1 
Meropenem/Rifampicin 1 
Meropenem/Tigecycline 26 
Rifampicin/Amikacin 3 
Rifampicin/Doripenem 1 
Rifampicin/Tigecycline 1 
Rifampicin/Tobramycin 2 
Tigecycline/Doripenem 7 
Tobramycin/Doripenem 1 
Total 70 
Three Additional Agents 
Cefepime/Rifampicin/Amikacin 1 
Meropenem/Amikacin/Ciprofloxacin 1 
Meropenem/Rifampicin/Amikacin 1 
Meropenem/Tigecycline/Amikacin 3 
Meropenem/Tigecycline/Gentamicin 1 
Tigecycline/Doripenem/Pipperacillin Tazobactam 1 
Total 8 
 
 
3.2.7 De-escalation practices 
Of the patients who had cultures taken (n=210), in 74.3% (n=156) an organism was identified 
for which corresponding antibiotic sensitivity results were available to evaluate compliance 
to de-escalation practices. In 46.8% (73/156) of these patients, colistin was the only 
susceptible agent and de-escalation was therefore not possible. This demonstrates the extent 
of XDR infections in these settings and the reliance on colistin as the only viable treatment 
option for a substantial subset of patients. However, in 53.2% (n=83/156) of patients,  where 
sensitivity to at least one other feasible antibiotic agent was demonstrated, de-escalation or 
tailoring of directed therapy to an appropriate alternative antibiotic only occurred in 69.9% 
(58/83) of cases. No particular pattern in de-escalation could be established as this is due to 
prescriber preference. The de-escalated antibiotic selected was either a continuation of one 
of the combined antibiotics as monotherapy in 31% (n=18) of cases or, a completely new 
antibiotic agent in 69% (n=40). Detailed clinical information of these patients is unknown and 
whilst there may have been valid reasons to continue colistin therapy in these cases, the 
results suggest another colistin process measure that could be targeted for improvement.    
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For those patients for which therapy was de-escalated, the predominant antibiotic following 
de-escalation was meropenem 22.7% (n=15), levofloxacin 18.2% (n=12) and tigecycline 15.2% 
(n=10) (Figure 3.11). 
 
 
Figure 3.11. A breakdown of de-escalated antibiotic agents for the study patients 
 
3.2.8 Duration of therapy 
Duration of therapy was calculated as the sum of treatment days. A total of 6.1% (n=13) of 
study patients received a duration of colistin therapy for less than 72 hours. In order to avoid 
bias in the results, these patients will be excluded and thus the results pertaining to duration 
of therapy, effects on renal function and overall outcome of the remaining 199 patients will 
be discussed.  
The median duration of colistin therapy was nine days (interquartile range (IQR) 6-16 days; 
range 3-63 days). Most patients, 57.8% (n=115), received a course of therapy ≤10 days, 13.6% 
(n=27) between 11-14 days and 28.6% (n=57) ≥ 15 days. 
For those patients who received colistin for 15 days or more, the mean age was 49.7 years 
(range 19-83 years). The majority were male patients 64.9% (n=37) and were treated within 
the ICU 82.5% (n=47). At least one of the three major Gram-negative organisms were cultured 
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in 98.2% (n=56) of the patients. The average length of stay of these patients was 73.45 days 
(range: 16-227 days) and 36.8% (n=21) demised in hospital.    
 
3.2.9 Analysis of renal function 
Prior to the commencement of colistin, 2.0% (n=4) of patients were deemed to have kidney 
failure, 10.7% (n=21) severe kidney injury, 20.4% (n=40) moderate kidney injury and, 66.8% 
(n=131) normal kidney function, according to the kidney disease improving global outcomes 
(KDIGO) classification (KDIGO, 2013).    
The effects on renal function for patients who received IV colistin therapy in this study were 
found to be insignificant and no changes in renal function measured through SCr or eGFR 
were noted. The change in SCr level, as well as, the change in eGFR of study patient’s pre and 
post exposure to colistin is described in Figures 3.12 and 3.13. These study findings are similar 
to those described by Falagas et al. (2005) and Gibson et al. (2016) and could be as a result of 
the lower doses prescribed and shorter treatment durations found in this study.  
Furthermore, although the range in SCr of the patients studied was wide (Figure 3.12), most 
often, a medication is considered to have an adverse effect on the kidney if SCr increases by 
100% post exposure to the agent. In this study, no patient’s SCr post colistin exposure 
increased by 100% and only in a very small cohort of 5.6% (n=12) of patient’s, did SCr increase 
by more than 50% (range 54.3%-89.5%) following exposure to colistin. The wide range in SCr 
demonstrated by the 212 patients in the study could be attributed to the critically ill nature 
of the patient population for which variable kindey function is to be expected. The various 
categories of renal function according to the KDIGO classification of the patients studied prior 
commencement of colistin has already been described. Unfortunately, no additional variables 
such as the presence or absence of renal replacement therapy, other medications prescribed 
and clinical notes were available to elucidate the exact reasons for the wide range in SCr of 
patients studied.  
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Figure 3.12. Evaluation of the effects of serum creatinine (SCr) pre and post study patient’s 
exposure to colistin therapy. a) The median creatinine level before colistin therapy was 73 
µmol/L (IQR 53-110 µmol/L; range 21-601 µmol/L). b) The median creatinine level after 
colistin therapy was 73 µmol/L (IQR 51-128 µmol/L; range 20-645 µmol/L). c) The mean 
change in creatinine level (post-pre treatment) was 0 µmol/L (sd 95; range -384 to 577 
µmol/L).  This mean change was not significantly different to zero (95% confidence interval 
for mean change:  -14 to 13 µmol/L).  
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Figure 3.13. Evaluation of the effects of estimated Glomerular Filtration Rate (eGFR) pre 
and post study patients exposure to colistin therapy. a) The mean eGFR level before 
treatment was 79 mL/min (sd 37 mL/min; range 8-150 mL/min). b) The mean eGFR level 
after treatment was 79 mL/min (sd 38 mL/min; range 7-150 mL/min). c) The mean change 
in eGFR level (post-pre treatment) was 0 mL/min (sd 28 mL/min; range -112 to 89 mL/min).  
This mean change was not significantly different to zero (95% confidence interval for mean 
change:  -4 to 4 mL/min).   
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3.2.10 Overall compliance to antibiotic stewardship process measures for study patients 
on intravenous colistin therapy 
In order to establish appropriate stewardship practices for colistin in this study, a stewardship 
bundle comprising of eight process measures was designed to determine the compliance to 
essential stewardship related principles for colistin utilization. The compliance of the 
antibiotic stewardship related process measures of the patients on IV colistin in this study are 
summarised in Table 3.8. The lowest compliance rate from this evaluation pertains to 
maintenance doses (50.0%), ‘hang time’ (66.3%) and de-escalation practices (69.9%). 
Appropriate compliance to duration of colistin therapy could not be audited since evidence 
alluding to what the appropriate duration should be is lacking and as a result, in real world 
practice, this is based on the patients’ clinical response to treatment. As such, the study 
patient’s composite compliance to the proposed colistin stewardship bundle is 81.2% at best 
(using only seven process measures due to duration not able to be assessed and dose 
compliance according to the SASOCP guideline). As a result of this evaluation, important 
stewardship related targets were identified to enable future recommendations. In addition, 
ensuring compliance with recording weight and incorporation of South African guidelines for 
colistin dosing in hospital policies, may further improve utilization.  
 
 
Table 3.8. A summary of the compliance rate of antibiotic stewardship process measures 
for patients prescribed intravenous colistin therapy 
Process measures Compliance rate % (n)  
1. Obtaining an appropriate culture prior to the 
commencement of colistin therapy 
99.1 (210) 
2. Prescription of a loading dose 93.9 (199) 
3. Prescription of an appropriate loading dose 90.4 (180) 
4. Prescription of appropriate maintenance dosing 
including adjustment according to renal insufficiency 
50.0 (74/148)* 
42.3 (88/208)† 
5. Compliance to antibiotic ‘Hang time’ 66.3 (116) 
6. Prescription of colistin in combination with another 
Gram-negative susceptible antibiotic  
98.6 (209) 
7. De-escalation of colistin therapy 69.9 (58) 
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Process measures Compliance rate % (n)  
8. Median duration of therapy 9 days 
*SASOCP guidelines † Visser Kift et al., 2014 
 
3.2.11 Patient outcome measures 
Infection with MDR pathogens and critical illness are factors that impact hospital LOS and 
overall outcome. For the patients studied (n=199), median ICU LOS was 31 days (IQR 15-52 
days; range 0-152 days). The overall hospital admission median LOS for these patients was 46 
days (IQR 25-83 days; range 3-227 days). The majority of patients, 70.4% (n=140), were 
discharged indicating a 29.6% (n=59) in-hospital mortality rate (Figure 3.14). 
 
Figure 3.14. Overall in hospital patient outcome for patients on intravenous colistin (n=199) 
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3.3 Evaluation of the study associations of patients who received intravenous colistin    
Further statistical analysis was conducted on the patients who received IV colistin therapy in 
order to establish any possible associations between colistin utilization and other variables 
such as renal function, dose, treatment duration, hospital location, specimen type and 
organisms. Any associations established could further inform suitable stewardship 
recommendations for the appropriate use of colistin in the future. 
 
3.3.1. The association between colistin dose (loading and maintenance) and renal function 
(eGFR) 
No significant associations were found between various categories of renal function and 
loading doses prescribed (Fisher’s exact test; p= 0.13). However, although obvious and 
expected, a strong significant association was noted between different categories of renal 
function and colistin maintenance dose prescribed; those patients with eGFR categories of 
more than 60 mL/min received higher colistin maintenance doses (chi-square test;  p <0.0001; 
phi coefficient= 0.52) which is in line with the renal function based dosing strategy of colistin. 
Figure 3.15 graphically indicates the percentage of patients per various categories of colistin 
dose received according renal function classifications. It is evident that those patients in the 
severe kidney injury classification (GFR <30mmol/L) received lower colistin doses; 48% of 
patients in this category received a range of colistin dose between 1-2.5 MU. This is 
contrasted by the patients classified with normal renal function (GFR >60mmol/L) where 
96.1% of patients in this category received a colistin dose of 3MU or higher.   
 
3.3.2. The association of the presence of a blood stream infection on duration of treatment 
and overall outcome 
The analysis could not establish significance in the median duration of therapy (Wilcoxon rank 
sum test; p= 0.39) nor overall outcome (Fisher’s exact test; p= 0.86) between patients who 
did or did not have a blood stream infection. 
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Figure 3.15. The various colistin doses prescribed according to renal function classifications 
for intravenous (IV) study patients. 
 
3.3.3. The associations between the presence or absence of the three prevalent Gram-
negative organisms and duration of therapy 
The median duration of colistin treatment for patients with P. aeruginosa (12 days; IQR 8-23 
days) was significantly longer than for those patients who did not isolate this organism (9 
days; IQR 6-15 days)(Wilcoxon rank sum test; p=0.044; r=0.14; small effect size). The reasons 
for this are unknown but in general perceptions are such that P. aeruginosa infections require 
longer durations of treatment. No significant differences in the median duration of colistin 
treatment were found between those patients who did or did not have K. pneumoniae 
(Wilcoxon rank sum test; p= 0.68) nor those patients who did or did not have A. baumannii 
(Wilcoxon rank sum test; p= 0.54).   
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3.3.4.  Comparison between hospitals one and two (Johannesburg) to hospitals three and 
four (Pretoria) 
Colistin loading doses (chi-square test; p<0.0001; Cramer’s V=0.46) and maintenance doses 
(p< 0.0001) were found to be moderately significantly higher in the Pretoria set of hospitals 
(Figure 3.16 and 3.17) which indicates a prescriber preference of higher dose utilization in 
hospitals three and four. In patients who survived, the median duration of colistin treatment 
in the Johannesburg hospitals (11 days; IQR 7-16 days) was significantly longer (Wilcoxon rank 
sum test; p= 0.44; r=0.17; small effect size) than for those in the Pretoria hospitals (8 days; 
IQR 6-13 days). In addition, the proportion of patients with A. baumannii infections was 
significantly (moderate) higher (Fischer’s exact test; p<0.0001; phi coefficient= 0.32) in the 
Johannesburg hospitals (20.8%) compared to the Pretoria hospitals (1.7%) and similarly for P. 
aeruginosa, although a weak significance (Fisher’s exact test; P=0.0010; phi coefficient=0.24), 
the proportion of patients was higher in the Johannesburg hospitals (32.5%) compared to the 
Pretoria hospitals (12.5%). No significant associations between cities and K. pneumoniae 
prevalence could be established (Fisher’s exact test; p=0.46).  
 
3.3.5. Comparison of patients in general wards and Intensive Care Units (ICU) with regards 
to colistin loading and maintenance doses and duration of therapy 
Colistin loading (chi-square test; p= 0.048; Cramer’s V=0.18) and maintenance doses (Fisher’s 
exact test; p= 0.028; phi coefficient=0.21) were significantly (weak association) higher in 
patients in ICU’s versus general wards (Figure 3.18 and 3.19). This may be due to the critically 
ill nature of patients in ICU’s and the need to optimise dosing for these patients to enhance 
treatment success. No significance could be established in the median duration of treatment 
for patients in ICU’s versus general wards (Wilcoxon rank sum test; p=0.41).  
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Figure 3.18. Comparison of colistin loading doses 
prescribed between general wards and Intensive 
Care Units 
Figure 3.19. Comparison of colistin maintenance 
doses prescribed between general wards and 
Intensive Care Units 
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Figure 3.16. Comparison of colistin loading doses 
prescribed between the hospitals located in 
Johannesburg (Jhb) and Pretoria (Pta) 
Figure 3.17. Comparison of colistin maintenance 
doses prescribed between the hospitals located 
in Johannesburg (Jhb) and Pretoria (Pta) 
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3.3.6 The association between duration of therapy and loading and maintenance dose  
Importantly, the median duration of colistin treatment for patients who received lower 
loading doses of 4-6 MU (20 days) was significantly longer than those patients who received 
higher loading doses of 11-12 MU (8 days) (Kruskal-Wallis test; p=0.040) (Figure 3.20). This 
concept of higher doses resulting in shorter durations of treatment was also found with higher 
colistin maintenance doses prescribed, as the median duration of treatment of those patients 
who received a 3 MU eight hourly maintenance dose (12 days) was significantly longer than 
that of patients who received a 4.5 MU twelve hourly maintenance dose (8 days) (Kruskal-
Wallis test; p=0.027) (Figure 3.21). It should be noted that only 17 patients received a dose of 
1-1.5 MU compared to 112 patients who received a 4.5 MU dose and, as such, the implied 
similar duration of therapy for these two categories of patients should be interpreted with 
caution as this does not reprersent a valid sample to suggest that lower doses of colistin 
render shorter durations of treatment (Figure 3.21). Since duration in this study was shorter 
for those patients who received higher doses this may infer that clinical stability and 
therapeutic efficacy might have been achieved sooner for these patients (which is in line with 
supporting evidence that attributes this to the faster attainment of steady state and optimal 
colistin drug concentrations) and thus allowing the ability to stop therapy sooner.  
 
 
 
 
 
 
 
 
 Figure 3.20. Associations between colistin 
loading dose and median duration of treatment. 
The error bars denote the interquartile range. 
Figure 3.21. Associations between colistin 
maintenance dose and median duration of 
treatment. The error bars denote the 
interquartile range. 
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3.3.7.  The association between overall patient outcomes and the presence or absence of 
each of the three qualifying organisms, colistin dose or duration of therapy. 
No significant associations could be found between patient outcome and a particular 
organism (Fisher’s exact test; K. pneumoniae p=0. 87; P. aeruginosa p= 0.44; A. baumannii > 
0.99). Furthermore, no significance could be established between patient outcome and 
colistin loading dose received (chi-square test; p= 0.83) and duration of treatment (Wilcoxon 
rank sum test; p= 0.20). However, probably the most crucial finding of this study, despite lack 
of severity of illness data, is that a significant moderate association between overall patient 
outcome and IV colistin maintenance dose prescribed was found. Deceased patients were 
associated with lower maintenance doses per interval compared to patients that survived 
(Fisher’s exact test; p=0.0037; phi coefficient= 0.26). This is evidenced by the proportion of 
patients per category described in Figure 3.22 where 31.6% of patients who demised received 
a maintenance dose of 1-2.5 MU versus 11.6% in the group that were discharged.  
 
Figure 3.22. Associations between colistin maintenance doses prescribed and patient 
outcome 
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3.4. Discussion 
This results of this study evaluated the current utilisation of IV colistin across multiple South 
African hospitals involving a large sample of patients. Through this process numerous 
opportunities for improved stewardship were identified. 
Recent recommendations in response to the emergence and spread of plasmid-mediated 
colistin resistance include: preserving colistin use for definitive treatment based on 
susceptibility testing, use of PK/PD indicators to ensure appropriate dosing, and use of 
empirical therapy in selected cases only (Al-Tawfiq et al., 2017). As is evidenced through the 
results presented, MDR of the three major Gram-negative organisms which compelled the 
use of colistin in this study was widespread. Compliance to obtaining a culture in this study 
was good (99.1%), however, the use of colistin in the 33.5% of patients studied that was 
deemed to be empiric is a concern and could be as a result of the severely immune 
compromised, neutropenic state of the majority of patients included in the study, where 
colistin may have been prescribed following poor clinical response to other broad-spectrum 
antibiotic agents including the carbapenem class. Other factors could comprise: continuous 
spikes in temperatures; numerous previous admissions with broad spectrum antibiotic 
exposure and; the relatively high suspicion and risk of MDR infections due to the prolonged 
hospital length of stay in this patient population.  
There is wide-spread global consensus that the empiric use of colistin outside of “clearly 
defined circumstances or for certain at risk categories of patients” is strongly discouraged in 
order to preserve the efficacy of the antibiotic for the future generations (Al-Tawfiq et al., 
2017). The “clearly defined circumstances” and “at risk categories of patients” referred to 
should be outlined and defined, as it is difficult to say currently that the use of colistin in the 
71 patients deemed to have received empiric therapy in this study is justifiable or not, as a 
consequence of the critically ill nature of this study patient population. 
Use of colistin in general wards is distressing due to the high risk and toxic nature (nephrotoxic 
and neurotoxic) of the antibiotic, which requires appropriate monitoring and supervision 
when administered for signs and symptoms including: changes in renal function, muscle 
weakness, peripheral neuropathy and visual disturbances to name a few.  
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Repeat courses of colistin therapy pose a concern to patient outcome as it may indicate the 
inability of the antibiotic to resolve the initial MDR infection (possibly due to inappropriate 
dosing) or, it highlights the risks of probable acquisition of multiple MDR infections for 
patients with prolonged hospital admissions, compelling the need for colistin therapy.  The 
exact reasons for repeat courses of colistin could not be definitively established, however, 
due to the absence of clinical notes and other important required data in the records 
reviewed for this study (refer to study limitations in Chapter 6, Section 6.2). In addition, often 
these courses were administered prior to the study data collection period.  
According to colistin dosing  guidelines a colistin loading dose of 9-12 MU should be 
administered to patients regardless of renal function to rapidly achieve the necessary MIC 
concentration of 2 mg/L and prevent regrowth of more resistant pathogens (Visser-Kift et al., 
2014; Richards et al., 2015; Labuschagne et al., 2016; Nation et al., 2017). Furthermore, there 
is evidence to show that a maintenance dose of 4.5 MU administered 12 hourly rather than 3 
MU administered 8 hourly resulted in more favourable patient outcomes at day 7 (Dalfino et 
al., 2012), however, both dosing strategies equating to a total dose of 9 MU per day are 
acceptable for patients with normal renal function (Richards et al., 2015; Labuschagne et al., 
2016; Nation et al., 2017). Dose adjustments are also required for patients with compromised 
renal function based on available evidence due to the nephrotoxic nature of the drug (Falagas 
et al., 2009; Dalfino et al., 2012; Ortwine et al., 2014). The recommended frequency of colistin 
administration is either at eight or twelve- hourly intervals depending on the maintenance 
dose prescribed (Richards et al., 2015; Labuschagne et al., 2016). Longer dosing intervals, such 
as 24- hourly schedules, have demonstrated greater emergence of bacterial resistance to 
colistin compared to shorter intervals (Bergen et al., 2008).  
Contrary to these guideline recommendations, the findings of this study suggests that both 
loading and maintenance dosing of colistin is variable and inconsistent, with adherence to 
available local dosing guidelines at best 50.0%. This reveals the extent of uncertainty 
associated with colistin utilisation in SA hospitals and the very urgent need for education so 
that our last-resort Gram-negative antibiotic can be preserved for as long as possible.  
The poor compliance to appropriate colistin dosing demonstrated in this study is concerning. 
Since evidence has shown the importance of dosing colistin correctly to ensure favourable 
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patient outcomes, it is distressing to observe the huge variation in doses prescribed and the 
non-compliance to appropriate dose based on various categories of renal function and the 
incongruity in the prescription of a correct loading dose (Tables 3.5 and 3.7). The 
administration of a colistin loading dose is widely considered to be best practice, as it 
facilitates the rapid achievement of optimal bactericidal concentrations (Garoznick et al., 
2011; Dalfino et al., 2012). Although compliance with the recommendation for a loading dose 
was high (93.9%), the actual loading doses ranged from 4 MU to 12 MU. This too 
demonstrates a lack of understanding regarding the need for appropriate loading doses. 
There could be multiple factors that contribute to the poor dose compliance demonstrated 
by this study which could be established if physicians were interviewed to qualitatively assess 
and understand the exact reasons why to inform some behaviour change techniques in the 
future, however, some additional reasons are listed below;  
a) The historic ambiguity of the appropriate colistin dose could contribute to the lack of 
confidence in accurate prescribing. 
b) Prescribers may genuinely not know what dose to prescribe due to the complexity of 
the PK and PD of the drug in a critically ill patient. 
c) In general, compliance to recommended guidelines is often poor with much evidence 
indicating the need for behaviour change in prescribers particularly those of older age 
(Tell et al., 2015; Levy et al., 2015). It is also most likely that most clinicians are 
unaware of the available South African colistin dosing guidelines. 
d) Colistin is not commonly prescribed and only recently is re-emerging in South African 
hospitals as salvage therapy for critically ill MDR infections. As such, the prescription 
of colistin is not routine and may not be ‘second nature’ for prescribers as the 
prescription of other antibiotics may be. 
e) The prescription of colistin should be done according to renal function and there is no 
standardized dosing schedule as for most other antibiotics. This may further 
contribute to the lack of clarity regarding selection of the correct dose per category of 
renal efficacy for prescribers.   
 
The non-compliance demonstrated in this review indicates that although the tools and 
guidelines have been available to use in order to optimize colistin dosing, these have largely 
83 
 
been ignored or have not been widely disseminated. Regardless of the possible reasons stated 
above, since the pipeline for effective antibiotics is diminishing for serious MDR Gram-
negative infections and colistin is currently the final option, it is critical that each time it is 
prescribed, it is done appropriately to achieve rapid therapeutic serum concentrations in 
order to maintain the efficacy of the antibiotic, prevent the emergence of resistance and offer 
the patient his/her best chance of survival.  
In patients with severe sepsis and septic shock, the prompt administration of the right 
antibiotic can be lifesaving (Kumar et al., 2006; Rhodes et al., 2017). ‘Hang time’ is a colloquial 
term that describes the time lapsed from when an antibiotic is ordered/ prescribed to the 
time of actual IV administration which aims to be within one hour (Messina et al., 2015). The 
concept most commonly relates to the first dose of the first administered antibiotic as this is 
the highest impact opportunity for patient survival. Since according to best practices, colistin 
should only be prescribed following microbiological confirmation of its indication and is often 
escalation therapy (unlikely to be the first administred antibiotic), delays in colistin 
prescription and administration have been reported of up to 96 hours (Tigen et al., 2013).  
Delays in the prompt administration of colistin could be attributed to the Section 21 approval 
process that is required prior to the procurement of colistin (Visser-Kift et al., 2014) amongst 
other factors. This process can delay the timely administration of the antibiotic since 
application to the MCC and authorization thereof is needed – a process which can take one 
to three days in itself. This could negatively impact patient outcome if stock of colistin takes 
two to five days post-approval to be delivered depending on the hospital location. The section 
21 approval and procurement process of colistin was not included in the scope of this study 
and so metrics on the date of MCC application completion, date of MCC submission, date of 
approval, date of stock ordering and, date of stock delivery, were not evaluated. Additional 
factors that could have contributed to a delay in ‘hang time’ of the patients studied include 
(Messina et al., 2015): 
- The use of paper based prescription charts as opposed to electronic prescription entries; 
- Delays in the prescription evaluation, dispensing and processing time within pharmacies; 
- Delays in delivery of medication from the pharmacy to the wards; 
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- Delays in the reconstitution of the medication by nursing staff as often these wait for 
standardised medication administration rounds; 
- Often if ‘stat’ is not written on the prescription chart then the administration of the 
antibiotic is not considered urgent. 
Combination therapy was prescribed to the majority of patients (98.6%) in this study. This 
practice, including duplicate and sometimes triplicate therapy, is recommended by local 
guidelines for the treatment of CPE, suggesting that combinations may improve efficacy and 
minimise the risk of resistant organism selection. Studies that have supported combination 
therapy for CPE have relatively low sample sizes, and concerns remain regarding the increased 
environmental burden of multiple antibiotic exposure, which may actually increase host 
colonisation with resistant organisms and increase the risk of Clostridium difficile infection 
(Paul et al., 2014). The spectrum of antibiotics listed as combination agents in Figure 3.12 is 
interesting but since there is no standard protocol of the appropriate agent of choice, the top 
five co-administered antibiotics as demonstrated by this study all have evidence for efficacy 
in combination with colistin and could be deemed appropriate.   
 
For 69.9% (n=58) of the eligible patients, therapy was de-escalated to a narrower-spectrum 
antibiotic following the availability of sensitivity results. Although this is a somewhat low 
figure, it is in line with other studies indicating that de-escalation is not always possible for 
many reasons, including the limited number of effective antibiotics available to treat MDR 
infections, the limited understanding of how to de-escalate, and the fact that the practice has 
still not been widely accepted in critically ill patients (Garnacho-Montero et al., 2015). 
 
Evidence pertaining to the appropriate duration of colistin therapy is lacking since treatment 
is often definitive and continues until resolution of the infection or clinical response. Table 
3.9 compares the duration of therapy of this study to other international publications. As 
depicted, this study showed the shortest median duration of therapy when compared to 
others. The reasons for this are unknown but could possibly be due to higher doses used in 
some patients resulting in the faster attainment of therapeutic concentrations and perhaps 
quicker microbiological and or clinical cure (Dalfino et al., 2012). 
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Table 3.9. A comparison of the median duration of colistin therapy according to available 
published evidence 
Number of patients 
Median duration of colistin 
therapy (days) 
Reference 
24 13.5 Markou et al., 2003 
12 14.7 Sabuda et al., 2008 
258 17.9 Falagas et al., 2009 
28 11 Dalfino et al., 2012 
109 10 Tanita et al., 2013 
127 10.4 Gibson et al., 2016 
199 9 This study 
  
Colistin-related nephrotoxicity remains an important concern and has been found to be 
influenced by elevated plasma drug concentrations (>2.5 mg/L) and longer duration of 
therapy (Hartzell et al., 2009). Similar insignificant effects as in this analysis of renal function 
have been demonstrated (Dalfino et al., 2012). Another study found that up to 43% of 
patients were at risk of or had acute kidney injury or renal failure according to the Risk, Injury, 
Failure, Loss and End-stage kidney disease (RIFLE) criteria after IV colistin therapy; however, 
this toxicity was reversed following discontinuation of treatment (Pogue et al., 2011). Recent 
results from the multicentre PK colistin study demonstrated that there was huge interpatient 
variability in the clearance of colistin (even at similar creatinine clearances), which is probably 
due to differences between individuals in conversion rates of the inactive prodrug to its active 
form (Nation et al., 2017). This adds to the complexity of providing optimal dosing, given the 
very narrow therapeutic window of the drug. Due to the critically ill nature of the  patients in 
this study, many of whom required colistin as the only viable option for treatment of their 
MDR infections, the risk benefit ratio of renal toxicity versus prospect of survival was likely 
applied in an attempt to ensure better patient outcome.  
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The in-hospital mortality rate of the patients studied was 29.6%. It is difficult to compare the 
patient outcomes of this study to other publications as the definition of these outcomes, 
inclusion criteria and doses used vary between studies. In addition, a limitation of this study 
relates to lack of multivariate analysis of significant risk factors for mortality such as severity 
illness scores, percentage of patients receiving high risk indwelling therapies such as 
mechanical ventilation and renal replacement therapy, as well as, other co-morbidities. 
 
The study patient’s composite compliance to the proposed colistin stewardship bundle is at 
best 81.2% with the lowest compliance indicators relating to maintenance dose, de-escalation 
practices and ‘hang time’.The findings of the study support the call for optimal colistin dosing 
to improve patient care and outcome and reiterates the need to ensure sufficient colistin 
dosing for critically ill patients. Since the results described prove that patients’ who received 
higher colistin loading and maintenance doses had a shorter duration of therapy and more 
favourable overall in-hospital outcomes (Figures 3.23-3.25). This could be due to the 
concentration dependent nature of the drug and is in keeping with the concept that the 
optimal administration of antibiotics according to PK principles and rapid achievement of 
therapeutic concentrations would result in improved clinical cure (Dalfino et al., 2012; Vicari 
et al., 2013).  
 
3.5. Summary and Conclusions   
 The utilization of colistin spans both ICU and general wards in hospital settings. 
 There is poor compliance to local guideline-based recommendations of colistin dosing 
prescribed in the four South African hospitals studied. 
 Poor compliance relates to both loading and maintenance doses. 
 Compliance to other antibiotic stewardship process measures such as, taking a culture 
prior to therapy, prescription of a loading dose and, prescription of colistin in combination 
with another Gram-negative antibiotic was good.  
 In contrast, compliance to antibiotic ‘hang time’ and de-escalation once susceptibility 
results were available, is poor. 
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 Those patients with P. aeruginosa infection were found to be treated with colistin for 
longer durations compared to infections of other organisms. 
 Effects on renal function of colistin therapy on the study patients were insignificant. 
 Colistin loading and maintenance doses were found to be higher in the Pretoria Group of 
hospitals compared to the Johannesburg hospitals. 
 Those patients who received higher colistin doses were found to also receive a shorter 
duration of treatment. 
 Those patients who received higher colistin doses appear to have had better overall in-
hospital outcomes. 
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CHAPTER FOUR 
EVALUATION OF AEROSOLISED COLISTIN UTILIZATION ACROSS FOUR PRIVATE 
SECTOR HOSPITALS IN SOUTH AFRICA. 
 
4.1. Introduction 
Of the four hospitals studied, hospital one was the only institution which used inhaled colistin 
for the treatment of LRTI’s. Possible reasons for this could be due to hospital one being a 
centre of excellence for CF patients (for which inhaled colistin therapy is common practice) 
and the prescription of inhaled colistin therapy is similarly done for other LRTI’s. Also, the 
doctors that treat CF patients at this hospital may be the same as those attending to patients 
with LRTI’s in ICU’s and so similar drug delivery methodologies may be adopted across 
patients. Whereas, the other hospitals do not routinely treat CF patients and the concept of 
colistin inhalation therapy may not be common knowledge. As such, the lack of clinician and 
nursing experience may prohibit inhaled delivery in those settings. This chapter will review 
the results of 25 patients who received inhaled colistin therapy during the study period.  
 
4.2. Results  
4.2.1. General patient demographics 
A summary of the demographics of the 25 patients who received inhaled colistin therapy for 
both CF and other nosocomial pulmonary infections is described in Table 4.1. The mean age 
and gender of patients between the two groups are the predominant differentiating factors; 
those with CF being considerably younger and predominantly females than the patients with 
nosocomial LRTI’s.  
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Table 4.1. Demographics and characteristics of the patients studied receiving aerosolised 
colistin (n=25) 
Demographic                                                                                                       % (n) 
Number of patients per hospital                         
Hospital 1: 100.0 (25) 
Hospital 2: 0 (0) 
Hospital 3: 0 (0) 
Hospital 4: 0 (0) 
Number of patients according to treatment diagnosis 
Cystic fibrosis patients                                                                        52.0 (13) 
Other LRTI’s  (including VAP)                                                              48.0 (12) 
Distribution of patients according to hospital location 
General wards 64.0 (16) 
Intensive Care Units (ICU) 36.0 (9) 
Age 
Cystic fibrosis patients mean age 31.8 years 
Other LRTI’s patients mean age                                                         64.9 years 
Gender cystic fibrosis patients  
Male  23.1 (3) 
Female 76.92 (10) 
Gender other LRTI patients 
Male                                                                                                    75.0 (9) 
Female                                                                                                 25.0 (3) 
Course of aerosolised colistin therapy 
First Course 72.0 (18) 
Repeat Course 28.0 (7) 
Indication for aerosolised colistin therapy 
Directed therapy 88.0 (22) 
Salvage  therapy 12 (3) 
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A breakdown of the number of patients who received aerosolised colistin therapy according 
to various categories of admitting diagnoses is summarised in Figure 4.1.  
 
Figure 4.1. A breakdown of the number of patients per category of admitting diagnoses for 
patients included in the study on aerosolised colistin (n=25)  
 
4.2.2.  Microbial analysis for cystic fibrosis patients 
For the patients who were admitted for acute exacerbations of CF (n=13), 100% had cultures 
taken of which all grew P. aeruginosa. This is not surprising as previously described- this 
organism is the most common opportunistic pathogen detected in patients with CF 
particularly those of advanced age. A breakdown of the specimen type in which P. aeruginosa 
was identified is shown in Figure 4.2, indicating sputum as the most common sample used for 
organism detection in these patients.  
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Figure 4.2. A breakdown of the number of patients per category of specimen type tested 
for organism growth for patients included in the study with cystic fibrosis (n=13) 
 
4.2.3. Evaluation of Pseudomonas aeruginosa sensitivity profile of cystic fibrosis patients 
The cumulative sensitivity profile of the thirteen P. aeruginosa isolates identified from the 
patients with CF in this study is summarised in Figure 4.3. Efficacy of the carbapenems was 
poor with only a third of isolates showing sensitivity to any of the carbapenems active against 
pseudomonal species. Due to the poor sensitivity of the organism demonstrated, colistin was 
the only viable option available for treatment in these patients.  
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Figure 4.3. A cumulative antibiotic sensitivity profile of the thirteen Pseudomonas 
aeruginosa isolates detected in patients with cystic fibrosis in this study 
 
4.2.4. Dose and duration of therapy for cystic fibrosis patients 
The majority of CF patients (92.3%) received the appropriate dosing regimen of 2 MU inhaled 
12 hourly (as recommended by available South African guidelines) whilst only one patient 
(7.7%) received an inhaled dose of 1 MU 24 hourly. This reflects overall good compliance to 
best practice inhaled colistin dosing recommendations for CF patients. The appropriate 
duration of treatment for acute pulmonary exacerbations has not been definitely established, 
however, recommendations of 14 days but not exceeding 21 days exist (Elborn., 2016; Stefani 
et al., 2017). The median duration of colistin treatment of CF patients studied was 10 days 
(range 4-21 days) indicating a shorter than recommended course of therapy. Furthermore, all 
treatment was discontinued in 84.6% (n=11) patients and for 15.4% (n=2) of patients, IV 
cefepime was continued following discontinuation of colistin inhalation therapy.  
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4.2.5. Co-administered antibiotic therapy for cystic fibrosis patients 
All study patients with CF who received inhaled colistin therapy also received concomitant IV 
therapy with other antibiotics. A summary of additional IV antibiotics prescribed is depicted 
in Figure 4.4. For 23.1% (n= 3) of patients two additional antibiotics were prescribed and 
15.4% (n= 2) of patients received three additional antibiotics. Interestingly ceftazidime was 
the most commonly prescribed concurrent IV antibiotic possibly due to its quorum sensing 
ability and moderate efficacy against mucoid P. aeruginosa strains in chronic infections. 
 
Figure 4.4. Additional antibiotic agents chosen as concomitant intravenous therapy to 
inhaled colistin for the studied cystic fibrosis patients 
 
4.2.6. Cystic fibrosis patient outcome measures 
Of the 13 CF patients studied, 100% were discharged from hospital and the median hospital 
LOS was 15 days (5-46 days). Similar utilization studies showing overall hospital LOS in CF 
patients on colistin inhalation therapy could not be found in the literature to draw 
comparisons.  
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4.2.7. Microbial analysis of patients with other lower respiratory tract infections on 
aerosolised colistin 
In this study data regarding whether a patient was mechanically ventilated or not could not 
be established as this was not reliably recorded on the Bluebird® system. However, the 
aerosolised utilization of colistin in this subset of patients were due to an infection of the 
lower respiratory tract based on culture specimens taken and indication for treatment which 
could have included those of ventilator associated infection.   
Of the 12 patients included in this study who received colistin inhalation therapy for a LRTI 
(other than CF), 100% had cultures taken that also demonstrated growth. Organisms were 
cultured from either tracheal aspirates 66.67% (n=8), or sputum samples 33.3% (n=4). The 
organisms identified in these patients included: P. aeruginosa 50% (n=6), A. baumannii 33.3% 
(n=4) and  K. pneumoniae 16.7% (n=2). All organisms isolated were classified as MDR due to 
evidence of resistance to three or more antibiotic classes. A breakdown of the cumulative 
sensitivity per organism could not be accurately achieved due to the very small sample sizes 
of each of the identified organisms of this patient population; however, all isolates were 
sensitive to colistin.  
 
4.2.8. Evaluation of aerosolised colistin dosing and duration of therapy for patients with 
other multidrug-resistant lower respiratory tract infections 
A breakdown of the inhaled colistin dosing regimens prescribed for the 12 patients with LRTI’s 
is summarised in Table 4.2.  A large variation in prescribed inhaled colistin dose in these 
patients is evident and, no clear preference in appropriate dose regimen could be established 
from this evaluation.  
The median duration of inhaled colistin therapy of this subset of patients was 9.5 days (3-23 
days).  
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Table 4.2. Evaluation of the dosing regimens prescribed for patients with other multidrug-
resistant lower respiratory tract infections on inhaled colistin therapy 
Aerosolised dose prescribed in 
Million International Units (MU) 
Frequency of administration 
prescribed in hourly (hrly) intervals 
% of patients (n) 
1 8 33.3 (4) 
1 12 33.3 (4) 
2 8 8.3 (1) 
2 12 25.0 (3) 
 
 
 
4.2.9. Compliance of study patients with multidrug-resistant lower respiratory tract 
infections to South African aerosolised colistin dosing guidelines. 
The colistin dosing guideline by Labuschagne et al. (2016) included dosing recommendation 
for inhaled therapy. Compliance of the 12 patients’ inhaled colistin dose evaluated in this 
study to the guideline is poor at 41.7%. This indicates that only five patients were prescribed 
an accurate and appropriate dose according to local guideline recommendations (Table 4.3).  
 
Table 4.3. Study patients’ compliance to the South African Society of Clinical Pharmacy 
colistin dosing guideline for inhaled colistin therapy in LRTI’s (Labuschagne et al., 2016) 
Body weight Dosing recommendation 
<40 kg 0.5 MU 12 hrly 
> 40 kg 1 MU 12 hrly 
Recurrent or severe pulmonary infections 2 MU 8 hrly 
Study patients compliance to recommended dosing guidelines* 
 Compliant: 41.7% (n=5) 
Non-compliant: 58.3% (n=7) 
*patients for which weight data was missing were assumed to be >40kg as the study only 
included adults patients. 
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4.2.10. Co-administered antibiotic therapy for patients with LRTI’s. 
None of the patients studied in this subset received dual inhalation and IV colistin and only 
inhaled colistin with IV therapy of other antibiotics was prescribed. The majority 83% (n=10) 
of patients, received such concomitant antibiotic therapy and the choice of antibiotic agent 
was varied and determined by the prescriber (Figure 4.5). For 20.0% (n= 2) of patients two 
additional IV antibiotics were received and, 80.0% (n= 8) of patients received one additional 
IV antibiotic. Two patients (17%) were prescribed colistin inhalation therapy alone. 
  
Figure 4.5. A breakdown of combination agents of choice prescribed intravenously with 
inhaled colistin therapy for patients with nosocomial lower respiratory tract infections 
 
4.2.11. Lower respiratory tract infection patient outcome measures 
Of the 12 patients with LRTI’s on inhaled colistin treatment studied, 91.7% (n=11) of patients 
were discharged. The median ICU LOS of these patients was 38 days (8-145 days) and the 
median hospital LOS 74.5 days (8-195 days).  
 
 
 
2
1
2 2
1 1 1
2
0
0.5
1
1.5
2
2.5
Meropenem Cefepime Ceftazidime  Tigecycline Ertapenem Amikacin Doripenem Piperacillin
Tazobactam
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
Other administered concominant antibiotics
97 
 
4.3.  Discussion 
This study found that inhaled colistin therapy was only prescribed in one hospital. For those 
patients with CF, for whom inhaled colistin therapy is common practice, as expected MDR P. 
aeruginosa was the only organism identified. Compliance to recommended dosing guidelines 
was good  (92.3%) and appropriate antibitoic combination therapy was prescribed. The use 
of inhaled colistin has had to become a necessity for CF patients as a consequence of the 
escalating rates of MDR P. aeruginosa detected which is currently estimated at 18.1% (Yapa 
et al., 2014; Stefani et al., 2017). The risk of MDR P. aeruginosa has been shown to increase 
in the presence of diabetes, long term exposure to tobramycin and frequent acute 
exacerbations requiring IV therapy in hospital stays (Stefani et al., 2017). However, defining 
organism resistance according to conventional breakpoint concentrations achieved from IV 
therapy is not applicable when considered in the context of CF and the extremely high 
antibiotic concentrations achieved following inhaled administration (Stefani et al., 2017).    
Reported colistin resistance following aerosolised exposure ranges from 19-34% in CF 
patients (Beringer, 2001) and evidence of the spread of colistin resistant P. aeruginosa strains 
in CF patients in both the United Kingdom and Denmark exists (Stefani et al., 2017). Some 
evidence suggests that the resistance may be transient and reversed when exposure to a 
particular agent is stopped or switched, however; anti-pseudomonal combination therapy (IV 
and inhalation) in the treatment of CF patients is still advised, to limit the development of 
resistance, add synergy and, offer additional symptomatic relief (Doring et al., 2000). In 
addition, inhaled antibiotic therapy may not reach all areas of the lungs in CF patients, due to 
obstruction of the airways, and so adjunct systemic therapy is recommended to enhance the 
prognosis of P. aeruginosa infection in an effort to preserve the health of the lung tissue for 
as long as possible (Ciofu et al., 2015; Emiralioglu et al., 2016).  
The concept of antibiotic quorum-sensing inhibition has been studied in an attempt to break 
through the biofilm for the treatment of chronic mucoid P. aeruginosa infection. Quorum-
sensing is a mechanism that inhibits the production of certain elements that are involved in 
the development of the biofilm (such as extracellular DNA) to weaken the matrix and allow 
for antibiotic penetration into the organism (Ciofu et al., 2015). Antibiotics such as 
azithromycin, ciprofloxacin and ceftazidime have shown to inhibit quorum-sensing in P. 
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aeruginosa and are recommended co-administered agents for advanced stage CF patients 
(Koerner-Rettberg and Ballmann, 2014; Ciofu et al., 2015). 
The duration of inhaled colistin therapy for these patients, however, was found to be shorter 
than recommended (Elborn. 2016; Stefani et al., 2017). These patients could have received 
additional doses of inhaled colistin therapy as part of the take home medication prescriptions 
to continue therapy following hospital discharge.   
For patients with other LRTI’s in this study the large disparity of inhaled colistin doses 
prescribed and the variation in other co-adminstered IV antibiotics indicates a lack of 
consistency and understanding of the suitable dosing regimen to select in these patients. This 
could be due to the lack of consensus and limited guidelines available on appropriate inhaled 
colistin treatment regimens. 
The only available South African guideline that provides dosing recommendations for inhaled 
colistin in LRTI’s is that by Labuschagne et al. (2016).  Even though the sample size is limited 
for this subset of patients, it is the first evaluation of inhaled colistin therapy conducted in a 
South African private hospital for the treatment of LRTI’s. The evaluation, however, reveals 
that there is much improvement required in increasing compliance to the prescription of an 
appropriate inhaled colistin dose for nosocomial LRTI’s as currently compliance is at 41.7%. 
Furthermore, these patients all received inhaled colistin therapy without concomitant IV 
colistin therapy. Direct comparisons cannot be made relating to duration of therapy due to 
limitations of the literature in describing duration of inhaled colistin monotherapy without 
adjunctive IV colistin. The findings of this study (9.5 days) are comparable though to durations 
described in other studies where median durations of inhaled and concurrent IV colistin was 
administered for 7.5 days (Michalopoulos et al., 2005), 13 days (Kofteridis et al., 2010) and 
11.23 days (Demirdal et al., 2016).  
The in-hospital LOS demonstrated for patients with LRTI’s on inhaled colistin therapy is 
considerably longer than that documented in previous studies which revealed ICU LOS of 20.5 
days (Michalopoulos et al., 2005; Kofteridis et al., 2010). It is difficult, however, to make direct 
comparisons of patient outcomes on inhaled colistin therapy in this study to others due to 
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differences in treatment regimens, drug resistance profiles, organisms detected, and mean 
patient ages. 
 
4.4. Summary and conclusions  
 Inhaled colistin is not common practice across South African private hospitals as only one 
of the hospitals was found to prescribe colistin via the inhalation route. 
 Compliance to dosing recommendations of inhaled colistin for patients with CF is good at 
92.3% with only one patient evaluated deemed to have received an inappropriate dose.  
 All patients with CF were discharged from hospital and were found to receive a shorter 
median duration of colistin treatment compared to that noted in previously conducted 
studies. 
 There is poor compliance (41.7%) to guideline-based recommendations of inhaled colistin 
dosing for patients with MDR LRTI’s. 
 Patients with LRTI’s in this study received inhaled colistin therapy in combination with 
other IV antibiotics and none received both IV and inhaled colistin, which some authors 
suggest to be  best practice. 
 The total hospital LOS of patients with MDR LRTI’s was prolonged compared to CF patients 
and all but one patient was discharged.  
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CHAPTER FIVE 
REVIEW OF ORGANISM SENSITIVITY PROFILES AND RESISTANCE PATTERNS 
 
 
5.1. Introduction 
A review of the cumulative antibiotic sensitivity profiles (antibiograms) of the major 
organisms identified in this study, including K. pneumoniae, P. aeruginosa and A. baumannii, 
was obtained from analysis of the actual laboratory reports for which the results were issued 
per patient as available on the Bluebird® system. Antibiograms are used in clinical practice to 
select appropriate empiric and directed therapy for patients in a hospital; based on the 
bacterial environment and resistance patterns established as a result. Regrettably, due to the 
large proportion of missing data from susceptibility reports evaluated for many of the isolates, 
antibiograms according to their strict criteria could not be accurately produced for this 
analysis (ACSQHC, 2013). As such, syndromic antibiograms were developed, and will be 
evaluated, based on the specimen types of all patients included in the study that had more 
than 30 isolates identified per source. Blood (n=66) and sputum (n=31) study sample results 
met this criteria. In addition, the susceptibility of the three major Gram-negative organisms 
cultured in patients who received IV colistin treatment is reviewed.  
 
5.2. Results and discussion 
5.2.1.  The syndromic antibiogram established from the study blood samples 
A distribution of the organisms identified from the blood samples (n=66) of all study patients 
is depicted in Figure 5.1.  In total, nine species were identified, however, K. pneumoniae was 
the most predominant organism followed by P. aeruginosa and A. baumannii.  
The extent of resistance of the three major Gram-negative organisms identified in blood 
samples is described in Figure 5.2. The classification of MDR was defined as organisms that 
showed resistance to three or more classes of antibiotics and XDR as those only showing 
susceptibility to colistin. It is important to note that three isolates of K. pneumoniae from 
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blood samples were reported as colistin resistant, however, sensitivity to the carbapenems 
was described in these instances. All isolates of each of the three predominant Gram-negative 
species identified were classified as either MDR or XDR. Of the other Enterobacteriaceae 
identified in Figure 5.1, four were not classified as MDR or XDR for which the prescription of 
colistin could be deemed inappropriate. However, in most of these instances, and as 
discussed in previous chapters, colistin was prescribed empirically and then evidently de-
escalated in 69.9% of patients when sensitivity reports became available. The remaining 11 
isolates for the other organisms identified were also classified as MDR and therefore 
compelled the use of colistin for the study patients.  
Figure 5.1. Species distribution identified from blood samples (n=66) of patients included in 
this study 
Figure 5.2 Major Gram-negative organisms as a function to resistance in bacteraemia of 
patients included in the study 
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The cumulative antibiogram for bacteraemic pathogens is illustrated in Figure 5.3. This 
indicates the percentage resistant versus susceptible for all the organisms identified from the 
blood samples studied. Percentage calculations were based on the total number of samples 
tested for susceptibility per antibiotic. As can be noted, substantial resistance of the 
bacteraemic pathogens for many of the antibiotics is depicted, in particular for the β-lactams 
such as cephalosporins and those with additional enzyme inhibitors. Furthermore, the 
sensitivity of the carbapenems: ertapenem (56.0%), doripenem (59.0%), imipenem (61.0%) 
and meropenem (62.0%) suggest their role as empiric monotherapy for sepsis in this setting 
is limited. This is because only those antibiotics that exhibit sensitivities greater than 90.0% 
are usually selected for therapy of bacteraemia and then, it is essential that the drug delivery 
is optimised to give the patient the best chance of survival (Deresinski, 2007). Therefore, for 
the bacteraemic pathogens in this study, colistin was the most active agent considering 95.0% 
susceptibility to all organisms was observed. The evaluation of organism sensitivity and the 
extent of resistance identified in these pathogens highlights the magnitude of the threat of 
antibiotic resistance facing patients currently in South African hospitals.    
 
Figure 5.3. Cumulative antibiogram from bacteraemic pathogens (n=66) identified in the 
study 
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5.2.2. Syndromic antibiogram established from the study of sputum samples 
A distribution of the organisms identified from the sputum samples (n=31) of all study 
patients is depicted in Figure 5.4. Fifteen of these pathogens were cultured in patients who 
received inhalation colistin therapy. Only four species were isolated from the respiratory tract 
with P. aeruginosa the most predominant pathogen. This is to be expected due to the 
inclusion of patients with CF in the study (Chapter four). Klebsiella pneumoniae was the 
second most commonly identified species followed by A. baumannii and E. cloacae.  
 
Figure 5.4. Species distribution identified from sputum samples (n=31) of patients included 
in this study 
 
Evaluation of the three major Gram-negative pathogens identified from sputum samples as a 
function of resistance is illustrated in Figure 5.5. All (n=3) the A. baumannii pathogens were 
classified as MDR. The extent of resistance amongst K. pneumoniae (n= 7) was demonstrated 
with the majority classified as MDR (n=6) and one isolate XDR. Furthermore, only two P. 
aeruginosa isolates were not MDR or XDR. The one E. cloacae isolate was shown to be colistin 
resistant; however, sensitivity to numerous other classes of antibiotics was reported. This 
could possibly indicate hetero-resistance of this strain of E. cloacae to colistin which was 
recently described by Napier et al. (2014).  
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The cumulative antibiogram for pathogens identified from sputum samples is described in 
Figure 5.6. Due to P. aeruginosa being the principal organism in this subset, only those 
antibiotics for which data was available and which demonstrate pseudomonal activity were 
included in the figure. Similar to that discussed in Section 5.2.1 for blood samples, the 
sensitivity of the β-lactam antibiotics including the cephalosporins and piperacillin- 
tazobactam, as well as, the quinolones (ciprofloxacin) and aminoglycosides (gentamicin and 
tobramycin) was shown to be ≤ 35% for the P. aeruginosa isolates obtained from sputum. The 
poor activity of the carbapenems: imipenem (35%), meropenem (42%), doripenem (44%) is 
concerning and demonstrates the species’ inherent ability to accumulate resistance. Amikacin 
demonstrated susceptibility greater than 50% but even this is too low to support the empirical 
use of this agent as monotherapy. Once again, colistin was the most active agent 
demonstrating 97% sensitivity amongst Gram-negative bacteria cultured from the respiratory 
tract.  
 
Figure 5.5. Major Gram-negative organisms as a function to resistance in sputum sources of 
patients included in the study 
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Figure 5.6. Cumulative antibiogram from sputum pathogens (n=31) identified in the study 
 
5.2.3. Cumulative susceptibility of the three major Gram-negative organisms in patients 
who received intravenous colistin (all sources) 
The susceptibility profile of the three predominant Gram-negative organisms cultured from 
patients who received IV colistin therapy were combined and also evaluated. The respective 
cumulative sensitivity profiles are depicted in Table 5.1 for K. pneumoniae, P. aeruginosa and 
A. baumannii. The results of A. baumannii need to be interpreted with caution since there are 
less than 30 isolates tested for this organism and therefore deductions regarding 
susceptibility cannot reliably be made based on the rules for antibiograms (ACSQHC, 2013). 
With this in mind colistin was shown to be 100% sensitive to all the A. baumannii isolates 
(n=18) for which it was tested and tigecyline was the next most susceptible agent (77.0%; 
n=13).  
The resultsfor K. pneumoniae and P. aeruginosa, however, meet the criteria for validity and 
as such can be evaluated. Of the K. pneumoniae (n=67) and P. aeruginosa (n=39) isolates 
tested for colistin susceptibility, 93.0% and 97.0% were reported as colistin sensitive 
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10.0%, 8.0% and 6.0% of isolates were sensitive to imipenem, meropenem and doripenem, 
respectively. For K. pneumoniae: susceptibility to imipenem, doripenem, meropenem and 
ertapenem was 72.0%, 71.0%, 68.0% and 38.0% respectively. These results highlight the 
inefficacy of the carbapenem class of antibiotics as single therapeutic options for either of 
these two organisms, which is not surprizing given the fact that colistin is often used for 
suspected CPE. The 2nd most active antibiotic against both organisms was amikacin although 
cumulative susceptibility was only 30.0% for P. aeruginosa and 80.0% for K. pneumoniae.  
 
Table 5.1 Cumulative antibiotic sensitivity profile of K. pneumoniae, P aeruginosa and A. 
baumannii isolates from patients who received intravenous colistin therapy 
Antibiotic 
Klebsiella pneumoniae 
(n=78) 
Pseudomonas 
aeruginosa (n=40) 
Acinetobacter baumanii 
(n=18) 
n % R* % S* n % R* % S* n % R* % S* 
Amikacin 65 20 80 40 70 30 17 59 41 
Cefepime 73 95 5 32 78 22 n/a n/a n/a 
Ceftazidime 54 94 6 33 79 21 n/a n/a n/a 
Ceftriaxone 68 96 4 n/a n/a n/a n/a n/a n/a 
Cefuroxime 73 96 4 n/a n/a n/a n/a n/a n/a 
Ciprofloxacin 74 84 16 40 75 25 n/a n/a n/a 
Colistin 67 7 93 39 3 97 18 0 100 
Doripenem 52 29 71 34 94 6 15 93 7 
Ertapenem 61 62 38 n/a n/a n/a n/a n/a n/a 
Gentamicin 74 80 20 38 74 26 18 89 11 
Imipenem 60 28 72 39 90 10 17 94 6 
Meropenem 60 32 68 40 93 8 17 94 6 
Piperacillin- 
Tazobactam 
73 96 4 38 82 18 n/a n/a n/a 
Tigecycline 57 33 67 n/a n/a n/a 13 23 77 
Tobramycin 65 92 8 39 69 31 17 71 29 
*R= resistant; S= sensitive, n/a= antibiotic does not demonstrate activity against this organism  
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The analysis of the sensitivities of these three predominant Gram-negative organisms 
identified in the study for patients on IV colistin indicate that no therapeutic alternatives were 
available as treatment options for the drug-resistant Gram-negative infections observed in 
the study.  
 
5.2.4. Evaluation of the Minimum inhibitory concentrations (MIC) of the three major 
Gram-negative organisms  
The MIC is defined as the minimum antibiotic concentration required to impede the 
observable growth of an organism (Andrews, 2001). In this study, only 30.2% (n=71) of 
isolates were submitted for MIC determination. No MIC tests were performed on A. 
baumannii isolates.  
Of the K. pneumoniae isolates tested, 67.9% (n=53) had MIC results available on the 
laboratory reports (Table 5.2). The median MICs  for this organism were lower than the MIC 
breakpoint of < 2.0 mg/L for the carbapenems except for ertapenem (range 0.032-32 mg/L) 
and for colistin was 0.5 mg/L (range 0.125-32 mg/L) (The European Committee on 
Antimicrobial Susceptibility Testing, 2017). Minimum inhibitory concentrations were 
available for only 30% (n=12) of the P. aeruginosa isolates, cultured from patients on IV 
colistIn. The median MIC of colistin for P. aeruginosa (n=12) was 1.0 mg/L (range 0.5 – 2.0 
mg/L) (Table 5.3). This data should be interpreted with caution due to the small sample size.  
The analysis of the available MIC data for this organism indicates the level of carbapenem 
resistance of these isolates, which would require antibiotic doses at unsafe and toxic levels, if 
colistin were not available as a treatment option.  
In this regard, the MIC50 and MIC90 (minimum antibiotic concentration required to inhibit 
50.0% and 90.0% growth of each species) was calculated for both K. pneumoniae and P. 
aeruginosa and described in Table 5.4. The present colistin MIC50 (0.5 mg/L) and MIC90 (1 
mg/L) for MDR and XDR K. pneumoniae infections in the study of IV colistin patients was 
shown to be below breakpoint and thus currently a viable option for treatment. For P. 
aeruginosa the MIC50 and MIC90 of all tested antibiotics were multiple folds above their 
respective breakpoints, except for colistin where this was determined to currently be 0.5 
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mg/L and 1 mg/L respectively. The MIC data indicates the extreme levels of resistance 
reported for P. aeruginosa isolates in this cohort of patients where colistin is certainly the 
only remaining therapeutic agent available with achievable and safe MIC targets.  
 
Table 5.2. Analysis of the Minimum inhibitory concentrations (MIC) of various antibiotics 
tested against K. pneumoniae (n=53) isolates identified in patients who received 
intravenous colistin therapy 
   MIC   
Variable 
(breakpoint mg/L) 
n Median Interquartile range Minimum Maximum 
Colistin (2) 24 0.5 0.50 0.5 0.125 32.0 
Doripenem (1) 33 0.5 0.25 4.0 0.032 32.0 
Ertapenem (0.5) 50 3.0 0.50 8.0 0.032 32.0 
Imipenem (2) 51 1.0 0.50 4.0 0.25 32.0 
Meropenem (2) 52 1.0 0.50 6.0 0.064 32.0 
 
 
Table 5.3. Analysis of the Minimum inhibitory concentrations (MIC) of various antibiotics 
tested against P. aeruginosa (n=12) isolates identified in patients who received intravenous 
colistin therapy 
   MIC   
Variable 
(breakpoint mg/L) 
n Median Interquartile range Minimum Maximum 
Amikacin (8) 9 64.0 64.0 64.0 16.0 64.0 
Cefepime (8) 8 40.0 12.0 64.0 8.0 64.0 
Ceftazidime (8) 9 32.0 16.0 64.0 4.0 64.0 
Colistin (2) 11 1.0 0.5 2.0 0.5 2.0 
Imipenem (4) 10 16.0 16.0 16.0 2.0 16.0 
Meropenem (2) 10 16.0 16.0 16.0 1.0 16.0 
Piperacillin 
Tazobactam (16) 
9 128.0 128.0 128 8.0 128.0 
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Table 5.4. The MIC50 and MIC90 of antibiotic agents tested agaisnt K. pneumoniae and P. 
aeruginosa obtained following evaluation of all specimens tested for MIC in this study 
Klebsiella pneumoniae (n=53) 
  Amikacin Doripenem Ertapenem Imipenem Meropenem Piptaz Colistin 
MIC 50 
(mg/L) 
2.0 0.5 2.0 1.0 1.0 128.0 0.5 
MIC 90 
(mg/L) 
16.0 32.0 32.0 32.0 32.0 128.0 1.0 
Pseudomonas aeruginosa (n=12) 
  Amikacin Cefepime Ceftazidime Imipenem Meropenem Piptaz Colistin 
MIC 50 
(mg/L) 
64.0 64.0 64.0 16.0 16.0 128.0 0.5 
MIC 90 
(mg/L) 
64.0 64.0 64.0 16.0 16.0 128.0 2.0 
 
 
 
5.3. Summary and conclusion 
 Evaluation of the syndromic antibiograms revealed substantial resistance to the majority 
of antibiotics for the bacteraemic pathogens with colistin showing the greatest 
susceptibility (95%) to all organisms.  
 Similarly, for organisms obtained from sputum, the sydromic antibiotic demonstrated 
colistin as the only viable therapeutic option since 97% sensitivity was observed. The next 
most sensitive antibiotic agent in this cohort was amikacin showing an activity of only 
55%.   
 Cumulative sensitivity of the K. pneumoniae and P. aeruginosa isolates from all sources in 
patients who received IV colistin was 93.0% and 97.0% respectively with the inadequacy 
of the carbapenem class of antibiotics highlighted for both organisms. 
 For P. aeruginosa the MIC50 and MIC90 of all tested antibiotics were multiple times above 
their respective breakpoints except when considering colistin (0.5 mg/L ; 1 mg/L). This 
reveals the extent of resistance of this organism and highlights colistin as the only likely 
antibiotic possibility.  
 Antibiotic resistance patterns of the three major Gram-negative organisms identified from 
this study were similar regardless of specimen site (blood versus sputum).  
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 The extensive antibiotic resistance displayed by P. aeruginosa, K. pneumoniae and A. 
baumannii by this study, indicates the limited therapeutic options available against these 
organisms. 
 The current dependence on colistin as last and only feasible therapeutic alternative is 
emphasized against these organisms. 
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CHAPTER SIX 
THESIS SUMMARY, FUTURE RECOMMENDATIONS AND STUDY CONCLUSION 
 
 
6.1. Thesis Summary 
For the first time in South Africa, the utilization of colistin was studied across four private 
sector hospitals including 237 patients in order to establish how and why colistin is being 
used. In addition, patient outcomes following administration of this last resort antibiotic were 
established and evaluated. The pertinent study findings of IV and aerosolised colistin are 
summarised accordingly in Chapters three and four and the evaluation of the organism 
sensitivity profiles identified is described in Chapter five. This study aimed to achieve a 
baseline of colistin utilization in South Africa with the following objectives as outlined in 
Chapter one, to provide insight to enhance the appropriate use of this antibiotic in the future.  
 
Objective 1: To ascertain colistin utilization including: dose, dose frequency, route of 
administration and duration of treatment. 
 
Although many experts believe that colistin should be restricted for use in high level care units 
due to the toxic nature of the drug and need for enhanced patient safety monitoring in these 
units, the findings of this study suggest that colistin is used in both the intensive care and 
general wards of hospitals. This is necessitated due to the need to treat MDR and XDR 
pathogens outside of ICU’s which reflects on the extent and spread of antibiotic resistance 
across various patients. More patients in the ICU received IV colistin compared to those who 
received inhaled colistin. The study also found extremely poor compliance to local available 
colistin dosing guidelines and a large variation in colistin doses prescribed in both IV and 
aerosolised routes of administration for critically ill patients. This may be due to the 
complexity of appropriate colistin dosing and the lack of awareness of prescribers to optimise 
doses according to PK and guideline recommendations. These findings require urgent 
attention in order to improve compliance to colistin dose according to different renal function 
categories to enhance patient safety and successful treatment outcome. Furthermore, the 
112 
 
duration of treatment was found to be shorter in patients who received higher colistin IV 
loading and maintenance doses which further reiterates the need to ensure optimal colistin 
dosing.  
 
The dosing compliance of patients with CF, however, was found to be good and in accordance 
with guideline recommendations for these patients. The duration of inhaled colistin therapy 
for patients with cystic fibrosis was slightly shorter than that noted by other studies 
internationally.  
   
Objective 2: To ascertain which were the most prevalent infecting organism and source of 
infections that necessitate the use of colistin.  
 
The three major organisms for which colistin was prescribed in this study was P. aeruginosa, 
K. pneumoniae and A. baumannii, all of which demonstrated extremely high levels of 
resistance to all antibiotics including the carbapenems. Due to the high resistance rates noted 
in the study colistin was most often the only viable therapeutic option as salvage treatment 
for these patients. The most common source of organism growth of the patients studied 
included; blood, sputum, urine and tracheal aspirate samples.  
 
Objective 3: To establish if appropriate antimicrobial stewardship principles are practiced 
during colistin therapy. 
 
A colistin stewardship bundle was devised in this study (see Section 3.2.11) to measure 
compliance to possible stewardship related principles for the IV administration of colistin. 
Compliance to eight stewardship process measures was evaluated including: (1) obtaining an 
appropriate culture prior to the commencement of colistin therapy; (2) prescription of a 
loading dose; (3) prescription of an appropriate loading dose; (4) prescription of appropriate 
maintenance dosing including adjustment according to renal insufficiency; (5) compliance to 
antibiotic ‘hang time’; (6) prescription of colistin in combination with another Gram-negative 
antibiotic; (7) de-escalation of colistin therapy and (8) median duration of therapy. Following 
the assessment of the colistin utilization according to these principles, compliance was good 
although the lowest compliance noted was due to administration ‘hang time’, inappropriate 
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loading and maintenance doses prescribed (which were proven critical to patient outcomes) 
and deficiency of de-escalation practices. Therefore, improvement in several colistin process 
measures particularly maintenance dosing warrants immediate consideration. Similar 
findings relating to inappropriate doses were noted for patients who received inhaled colistin 
therapy for LRTI’s. Compliance to duration of therapy could not be established as 
recommendations are lacking in South African and international guidelines. Overall, 
composite compliance to the stewardship bundle proposed in this study for patients on IV 
colistin therapy was found to be 81.2% at best which warrants improvement in the future.  
 
Objective 4: To establish patient outcomes while on colistin therapy including effects on 
renal function, hospital length of stay and overall mortality. 
 
A 29.6% in-hospital mortality rate was observed in patients who received IV colistin with a 
median duration of ICU LOS of approximately a month and median overall hospital LOS of 
approximately six weeks. The effects of renal function following IV colistin administration 
were negligible and insignificant as no difference in renal function was noted pre and post 
colistin administration. This is in line with recent findings that colistin may not be as toxic as 
originally thought and that renal toxicity may be short-lived and reversed once treatment is 
stopped (Dalfino et al., 2012). The results of the outcome measures evaluated echo what is 
expected for critically ill patients with MDR infections including, prolonged hospital LOS and 
poor patient outcomes (Deresinski, 2007). Of importance to this study, patients who received 
higher colistin loading and maintenance doses were shown to have better in-hospital overall 
outcomes. All of the patients who received inhaled colistin for cystic fibrosis were discharged 
and their hospital LOS was considerably shorter than median hospital LOS of ten and a half 
weeks recorded for patients who received inhaled colistin for a MDR LRTI’s.   
 
6.2. Limitations of this study 
These included: 
 The retrospective nature and the need to collect data from electronic prescription records 
which were completed and captured by frontline pharmacists. 
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 The electronic system which did not have the facility to record parameters such as renal 
replacement therapy and patient weight. 
 The inability to access and review clinical notes and other clinical parameters including 
but not limited to: other medication prescribed, patient temperature, blood pressure and 
other indwelling devices. 
 The high numbers of patients that did not have their weight recorded made it difficult to 
calculate creatinine clearances using the Cockcroft-gault equation and thus compliance 
with the SASOCP dosing guidelines based on creatinine clearance may be skewed.  
 Although not an aim of the study, the illness severity score such as the APACHE II score 
were not recorded and therefore patient risk in relation to mortality or outcome could 
not be corrected for.  
 Duration of therapy could not be used as a stewardship process indicator due to the 
limited guidance available as to what an appropriate duration of IV colistin should be.  
 Finally, data on side effects of colistin other than nephrotoxicity were not actively 
investigated. 
 
6.3. Future recommendations  
This study has identified recommendations to improve the utilization of colistin going 
forward. As such and optimistically within five to ten years, the introduction of colistin 
therapeutic drug monitoring (TDM) would be useful to individualize and optimise dosing, 
given the variability of PK and PD parameters displayed in critically ill patients and the growing 
need to refine therapy and maintain the efficacy of the antibiotic for the future. However, 
this may not be a practically viable option in the current context of healthcare in South Africa. 
This is due to the additional infrastructure required by the laboratories, the anticipated 
associated costs and the limited amount of TDM currently in place which is largely reserved 
for the aminoglycoside class of antibiotics and vancomycin. 
In addition, the package insert of colistin should be updated and amended accordingly with 
the latest accurate PK and PD data. This will better inform and assist pharmacists and 
prescribers of the appropriate dosing strategies required to achieve therapeutic efficacy for 
critically ill patients, and serve as a quick and reliable reference.   
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As an immediate solution, however, the design and implementation of a national intravenous 
colistin antibiotic stewardship bundle (Table 6.1), to be implemented in all hospitals in which 
colistin is prescribed, is strongly recommended. The implementation of care bundles in 
antibiotic stewardship can assist in enhancing compliance to evidence-based quality 
measures which could in turn improve the utilization of the antibiotic agents. Bundles include 
a set of evidence-based measures that when implemented together are shown to produce 
better outcomes and have a greater impact than that of the isolated implementation of 
individual measures (Reser et al., 2012). Bundles also help to create reliable and consistent 
care systems in hospital settings since they are clear and concise, in addition to promoting 
multi-disciplinary collaboration (Reser et al., 2005; Reser et al., 2012).   
 
Table 6.1. Summary of the proposed intravenous colistin process measures as a stewardship 
bundle 
Process measures 
 Documentation and record of the patient weight. 
 Obtaining an appropriate culture prior to the commencement of colistin therapy. 
 Prescription of a loading dose. 
 Prescription of an appropriate loading dose. 
 Prescription of an appropriate maintenance dose including adjustment according to 
renal insufficiency. 
 Compliance to antibiotic ‘hang time’. 
 Prescription of colistin in combination with another Gram-negative antibiotic. 
 De-escalation of colistin therapy. 
 Duration of therapy. 
 
The goal of such a recommendation would be to collectively improve colistin utilization by 
increasing compliance to targeted stewardship principles - in particular to selection of the 
appropriate dose - which could have a marked impact on improving the appropriate use of 
colistin. As a set of audit measures, such an intervention would aim to minimize the risk of 
colistin resistance emerging. Once implemented, it would be of paramount importance to 
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compare compliance to process and outcome measures in an interrupted time series study 
(pre and post implementation of such a bundle) at individual hospitals or at a national level. 
Furthermore, changes in colistin susceptibility could be longitudinally monitored over time.  
 
6.4. Conclusion 
This study identified that stewardship opportunities for improving colistin prescription and 
utilization exist (for both administration routes), and recommends the implementation of a 
colistin stewardship care bundle to preserve colistin efficacy in the foreseeable future 
(Messina et al., 2017). Results of the study showed that those patients who received higher 
IV colistin doses demonstrated shorter durations of treatment and better overall in-hospital 
outcomes. The appropriate dosing of colistin is complex but this should not be reason enough 
to not get it right. As a result of the escalating rates of MDR and XDR Gram-negative organisms 
currently being experienced in South Africa, and evidenced by this study, pharmacists along 
with prescribers should take up the challenge and work collectively as a team to always ensure 
the appropriate use of colistin.  The consequences of not doing so could have devastating 
consequences for public health in South Africa and beyond. 
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Evaluation of colistin utilization in patients with multidrug- and extensive drug-resistant Gram-
negative infections in four private hospitals in South Africa. 
Angeliki Messina,1,2 Adrian Brink3 and Sandy van Vuuren1 
1Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the  
  Witwatersrand, Johannesburg, South Africa 
2Department of Quality Leadership, Johannesburg, South Africa 
3Department of Clinical Microbiology, Ampath Laboratories, Johannesburg 
 
 Purpose: The emergence of life-threatening multidrug-resistant (MDR) and extremely drug resistant 
(XDR) bacteria has been widely documented as a global threat to society. These ‘super-bugs’ have 
gained resistance mechanisms to almost all antibiotics currently available necessitating the use of 
older, more toxic drugs such as colistin, as salvage therapy. Whilst emergence and spread of colistin 
resistance was recently documented in South Africa, compliance to current dosing guidelines is 
unknown and no local information of why and how colistin is prescribed is available. The primary 
purpose of this study was therefore to evaluate the current utilization of colistin, in order to develop 
an antimicrobial stewardship intervention to improve compliance to colistin process measures with 
the goal of enhancing outcomes.  
 
Methods: Electronic patient records of all adult patients in four Johannesburg hospitals with colistin 
were retrospectively reviewed over a five month period. The following data was collected: patient 
demographics, organism results and antibiotic susceptibility profiles, diagnosis, indication for colistin 
use as well as - dose, duration of therapy, route, administration of a loading dose, prescription in 
combination or as monotherapy, de-escalation of therapy following organism results and effects on 
renal function. Evaluation of outcome measures included: overall mortality, Intensive Care Unit length 
of stay (LOS), and hospital LOS while on colistin therapy.  
 
Results: Evaluation of study results demonstrated that the mean age of the patient population (n=64) 
was 50 years of which 60.9% were male. Administration occurred mostly in the intensive care units 
(76.6%). Therapy was regularly administered intravenously (IV) (90.6%) followed by nebulisation 
(7.8%). The mean duration of colistin therapy was 13,6 days. The compliance rate of administration of 
a loading dose (95.8%) and as combination therapy (98.3%) was high, although daily dosing regimens 
in million units (MU) of colistin varied considerably from 1MU, 1,5MU, 2MU and 3MU IV 8 hourly to 
1,5, 2MU, 3MU, and 4.5 MU IV 12 hourly. Colistin was prescribed as directed or definitive therapy in 
73.4% of patients, with 26.6% of treatment being initiated empirically. Organisms justifying the need 
for colistin use include; Klebsiella pneumoniae (35.9%), Pseudomonas aeruginosa (26.6%) and 
Acinetobacter baumannii (15.6%). Outcomes measures reflect a 29.7% overall mortality rate and an 
average LOS for hospital (55.9 days) and ICU (37.4 days).  
 
Conclusions: The data suggests that several opportunities to improve appropriate colistin use exist 
particularly regarding the dose and duration of therapy. In contrast, compliance to loading dose 
administration was >90%. 
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Evaluation of colistin utilization across multiple South African private hospitals: Indeed it’s time 
for colistin stewardship. 
Angeliki Messina1,2, Adrian Brink3,4, Sandy van Vuuren2 
1 Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, South Africa 
2 Department of Quality Systems and Innovation, Johannesburg, South Africa 
3 Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, 
South Africa 
4 Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape 
Town, South Africa 
Introduction: The increased prevalence of multidrug-resistant Gram-negative infections in critically ill 
patients has resulted in the re-introduction of colistin, a previously considered toxic antibiotic, as 
rescue therapy. Although colistin resistance has been documented in South Africa, there is no local 
evidence as to why and how colistin is used in hospitals. This study aimed to evaluate the utilization 
of colistin in order to identify stewardship opportunities regarding its’ appropriate use in the future.  
Method: A retrospective electronic record review of adult patients on intravenous colistin therapy for 
more than 72 hours in four Gauteng private hospitals was conducted between 1 September 2015- 30 
June 2016. Evaluation of six colistin stewardship process measures (colistin bundle) were reviewed; 
obtaining a culture prior to therapy, administration of a loading dose, administration of the correct 
loading dose, maintenance dose modifications based on renal function, whether colistin was 
administered in combination and if de-escalation following culture and sensitivity results occurred. 
Outcome measures included; effects on renal function, overall hospital mortality, intensive care unit 
length of stay (LOS), and hospital LOS. 
Results: Results of 199 patients demonstrated a 75.9% composite compliance to the colistin 
stewardship bundle. Non-compliance was mainly due to incorrect loading and maintenance doses 
prescribed and inappropriate dose adjustment according to renal function. Compliance to local, 
current colistin dosing guidelines was at best 48.2%. Significantly shorter durations of treatment were 
found in patients who received higher loading doses (p=0.040) and in those that received maintenance 
doses of 4.5 MU twice daily vs 3MU three times daily (p=0.0027). In addition, more of the patients 
that demised received the 3 MU three times daily maintenance doses, compared to those who 
survived (p=0.0037; phi coefficient=0.26).   
Conclusion: This study demonstrated that many stewardship related opportunities to improve 
appropriate colistin utilization exist in particular relating to dose. Colistin stewardship should be 
implemented as a matter of urgency to preserve the efficacy of this last resort antibiotic.   
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Opportunities to optimize colistin stewardship in hospitalized patients in South Africa: Results of a 
multi-site utilization audit 
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FRCP; S van Vuuren1 PhD 
 
1 Department of Pharmacy and Pharmacology, Faculty of Health Sciences, University of the Witwatersrand, 
Johannesburg, South Africa 
2 Department of Quality Systems and Innovation, Johannesburg, South Africa 
3 Department of Clinical Microbiology, Ampath National Laboratory Services, Milpark Hospital, Johannesburg, 
South Africa 
4 Division of Infectious Diseases and HIV Medicine, Department of Medicine, University of Cape Town, Cape Town, 
South Africa 
5 Division of Critical Care, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg and 
Charlotte Maxeke Johannesburg Academic Hospital, Johannesburg, South Africa. 
 
Background. Colistin is an old antibiotic which has been reintroduced as salvage therapy in 
hospitalized patients as it is frequently the only agent active against Gram-negative bacteria. Various 
guidelines for colistin administration have led to confusion in establishing the appropriate dose which 
has potential for adverse consequences including treatment failure or toxicity. The emergence and 
spread of colistin resistance has been documented in South Africa (SA), but no local information exists 
as to how and why colistin is used in hospitals, and similarly compliance with current dosing guidelines 
is unknown.  
Objectives. To evaluate the current utilization of colistin in SA hospitals, in order to identify 
stewardship opportunities that could enhance the appropriate use of this antibiotic.  
Methods. Electronic patient records of adult patients on intravenous (IV) colistin therapy for more 
than 72 hours in four private hospitals were retrospectively audited over a ten month period (1 
September 2015- 30 June 2016). The following data was recorded; patient demographics, culture and 
susceptibility profiles, diagnosis and indication for use. Compliance with six colistin process measures 
were audited; obtaining a culture prior to initiation, administration of a loading dose, administration 
of the correct loading dose, adjustments to maintenance dose  according to renal function, whether 
it was administered in combination with another antibiotic and whether de-escalation following 
culture and sensitivity results occurred. Outcome measures included; effects on renal function, overall 
hospital mortality, intensive care unit length of stay (LOS), and hospital LOS. 
Results. Records of 199 patients on IV colistin were reviewed. Compliance with obtaining a culture 
prior to antibiotic therapy was 99%, prescription of a loading dose (93.5%), and prescription of colistin 
in combination with another agent (98.5%). However, overall composite compliance to the six colistin 
stewardship process measures was 75.9%. Non-compliance related to inappropriate loading and 
maintenance doses, lack of adjustment according to renal function, and lack of de-escalation was 
evident in two-thirds of cases. Significantly shorter durations of treatment were found in patients who 
received higher loading doses (p=0.040) and in those that received maintenance doses of 4.5 MU twice 
daily vs 3MU three times daily (p=0.0027). In addition, more of the patients that demised received the 
3 MU three times daily maintenance doses, compared with those who survived (p=0.0037; phi 
coefficient=0.26).   
Conclusion. The study identified multiple stewardship opportunities to optimize colistin therapy in 
hospitalized patients. The urgent implementation of a stewardship bundle to improve colistin 
utilisation is warranted.    
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